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resumo 
 
 
No decurso da evolução, enquanto os vertebrados desenvolviam um complexo 
sistema para prevenir as perdas de sangue, os hematófagos criavam 
mecanismos anticoagulantes capazes de contra-atacar a reposta hemostática 
do hospedeiro, por forma a facilitar a extração, o armazenamento e a digestão 
do sangue. Muitos destes mecanismos assentam na inibição específica da 
trombina, proteína que tem um papel central na hemostasia. Apesar do 
elevado número de inibidores naturais de trombina, apenas uma pequena 
parte foi caracterizada bioquimicamente e, dentro desta, só alguns inibidores 
foram estudados de um ponto de vista estrutural. De todos aqueles com 
estrutura conhecida, a boofilina é o único que possui dois domínios canónicos 
do tipo Kunitz. No entanto, apesar de possuir domínios canónicos, a boofilina 
inibe a trombina através de um mecanismo não-canónico, no qual o seu N-
terminal é inserido no centro catalítico da trombina enquanto que o domínio C-
terminal interage com o exosite I da proteinase. Além disso, ao contrário de 
todos os outros inibidores caracterizados, a boofilina, em complexo com a 
trombina, é capaz de interagir com uma proteinase serínica adicional do tipo 
tripsina. Esta segunda interação envolve unicamente o domínio N-terminal, 
presumivelmente através do loop reactivo. In vivo, é possível que para além de 
inibir a trombina, a boofilina seja também capaz de inibir outra proteinase 
serínica da cascata de coagulação como o fXa, resultando não só na inibição 
da trombina mas também na diminuição da sua produção. Este aspecto faz da 
boofilina um bom modelo para a desenvolvimento de novos anticoagulantes  
terapêuticos. Pretende-se, por isso, clarificar este segundo mecanismo de 
inibição através do estudo da interação entre a boofilina e a tripsina. A boofilina 
(D1D2) e o seu domínio N-terminal isolado (D1) foram expressos em Pichia 
pastoris. Ambas as proteínas foram purificadas por cromatografia de afinidade 
numa coluna de tripsina seguida, no caso da D1D2, por cromatografia de troca 
iónica. Uma vez purificadas, a constante de inibição de cada uma das 
proteínas foi determinada e a D1 foi cristalizada por difusão vapor. Os cristais 
obtidos eram ortorrômbicos (grupo espacial P212121), tinham uma percentagem 
invulgarmente baixa de solvente (23%) e difrataram com uma resolução 
mínima de 1.80 Ǻ. A estrutura cristalográfica da D1 releva uma conformação 
similar à observada no complexo trombina-boofilina. O complexo tripsina-D1 foi 
também preparado in vitro e a sua cristalização está em curso. 
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abstract 
 
During evolution, while vertebrates developed a complex system to prevent 
blood loss, blood-feeding animals evolved anticoagulant mechanisms to 
counteract the haemostatic response of their hosts in order to facilitate blood 
drawing, storage and digestion. Many of these anticoagulant mechanisms rely 
on the specific inhibition of thrombin, a central enzyme in haemostasis. 
Although a number of a natural thrombin inhibitors from haematophagous 
animals have been described only a few have been fully characterised 
biochemically, and even fewer have been studied from a structural viewpoint. 
From those structurally characterised to date, only boophilin displays two 
tandem canonical Kunitz fold domains. However, despite its regular BPTI-like 
domains, boophilin inhibits thrombin by a non-canonical mechanism, in which 
its N-terminus inserts into the active site cleft of thrombin, while the C-terminus 
Kunitz domain interacts with the exosite I of the proteinase. Moreover, in 
contrast to all the other natural thrombin inhibitors characterised, when in 
complex with thrombin boophilin retains the capability to interact with an 
additional (non-thrombin) trypsin-like serine proteinase molecule. In this second 
interaction only the N-terminal domain is involved, presumably through its 
conserved reactive-loop. In vivo, it is likely that besides inhibiting thrombin, 
boophilin can target another serine proteinase of the coagulation cascade, such 
as fXa. This would result not only in thrombin inhibition, but also in the 
impairment of thrombin generation, making boophilin a good model for the 
design of new therapeutic anticoagulants. For this reason, this work aimed at 
clarifying this second inhibition mechanism by studying the trypsin-boophilin 
complex. Boophilin (D1D2) and its N-terminal domain (D1) were expressed in 
Pichia pastoris. Both proteins were purified by immobilized-trypsin affinity 
chromatography followed, in the case of D1D2, by ion-exchange 
chromatography. Once purified, the inhibition constant of both proteins was 
determined and D1 was crystallized by vapour diffusion. The crystals obtained 
were orthorhombic (space group P212121), had an unusually low solvent 
content of 23% and diffracted X-rays to beyond 1.80 Ǻ. The crystallographic 
structure of the first domain of boophilin reveals a conformation of the reactive 
site loop similar to that observed in the thrombin-boophilin complex. The D1-
trypsin complex was also prepared in vitro and its crystallization is underway. 
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Abbreviations 
 
 
ADP Adenosine diphosphate 
Ala Alanine 
APS Ammonium persulfate 
Arg Arginine 
Asp Aspartic acid 
AU Absorbance units 
BIS-TRIS Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane 
BMGY Buffered glycerol-complex medium 
BMMY Buffered methanol-complex medium 
BSA Bovine serum albumine 
Bz Benzoyl 
cDNA Complementary deoxyribonucleic acid 
gDNA Genomic deoxyribonucleic acid 
Cys Cysteine 
C-terminus Carboxyl-terminus 
D1 Isolated first domain of boophilin 
D1D2 Full-length boophilin 
DIC Disseminated intravascular coagulation 
dATP 2'-deoxyadenosine 5'-triphosphate 
dCTP 2'-deoxycytidine 5'-triphosphate 
dGTP 2'-deoxyguanosine 5'-triphosphate 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide triphosphate 
dTTP 2'-deoxythymidine 5'-triphosphate 
EDTA Ethylenediaminetetraacetic acid 
gDNA Genomic deoxyribonucleic acid 
Gln Glutamine 
Glu Glutamic acid 
Gly Glycine 
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His Histidine 
Ki Inhibition constant 
Km Michaelis-Menten constant 
LB Luria-Bertani 
Lys Lysine 
MES 2-Morpholinoethanesulfonic acid monohydrate 
MOPS 3-(N-Morpholino)propanesulfonic acid 
MPD 2-Methyl-1,3-propanediol 
N-terminus Amino-terminus 
NPGB 4-nitrophenyl 4-guanidinobenzoate hydrochloride 
OD Optical density 
PAI Plasminogen activator inhibitor 
PAS Periodic acid-Schiff 
PCR Polymerase chain reaction 
PEG Poly(ethylene) glycol 
Phe Phenylalanine 
pI Isoelectric point 
pNA 4-nitranilide 
rpm Rotation per minute 
Ser Serine 
SDS  Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate – polyacrylamide  
gel electrophoresis 
SOC Super optimal broth 
TAE Tris, acetic acid, EDTA 
TAFI Thrombin activatable  fibrinolysis inhibitor 
TAFIa Activated thrombin activatable  fibrinolysis inhibitor 
TE Tris-HCl, EDTA 
TEMED N,N,N',N'-Tetramethylethylenediamine 
TF Tissue factor 
TFB I Standard transformation buffer I 
TFB II Standard transformation buffer II 
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TFPI Tissue factor pathway inhibitor 
tPA Tissue-type plasminogen activator 
Tris Tris(hydroxymethyl)aminomethane 
Val Valine 
Vmax Maximum reaction rate 
YPD Yeast peptone dextrose 
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1.1. Haemostasis 
 
 Haemostasis is a group of well-regulated processes that are responsible for 
keeping the blood fluid and for avoiding blood loss after a vessel injury by the 
formation of a fast and local haemostatic plug. Normal haemostasis depends on 
the closely integrated and coordinated action of vascular wall, platelets and 
coagulation factors (Cotran et al., 2000).  
 After a vessel injury, the smooth muscle cells of the vessel wall contract in 
order to minimize blood loss. The platelets adhere to the collagen of the 
subendothelial matrix that is exposed by the vessel injury. Platelets become 
activated suffering morphological changes and releasing the content of large 
vesicles named granules. These granules contain adhesion proteins (fibrinogen 
and thrombospondin), serotonin (that promotes retention of procoagulant proteins 
on the platelet surface), ADP and other platelet-activating factors. Besides 
collagen, the cell membrane tissue factor (TF) is also exposed, and both initiate 
the coagulation cascade (Cotran et al., 2000). 
 
 
1.2. Coagulation cascade 
 
The coagulation cascade (Figure 1) has been traditionally presented as two 
relatively independent pathways: the intrinsic and the extrinsic pathways that 
converge into a common pathway (Ajjan and Grant, 2006; Cotran et al., 2000; 
Furie and Furie, 1988).  
The intrinsic pathway is initiated by the activation of factor (f) XI, which in 
turn activates fIX to fIXa. FIXa in complex with its cofactor fVIIIa activates fX, 
initiating the common pathway (Cotran et al., 2000). The physiological initiator of 
the intrinsic pathway is not clear (Thiagarajan and Narayanan, 2001). The release 
of collagen from the subendothelial layer, after vessel injury, has been suggested 
as the initiator (Cotran et al., 2000). In vitro, this process can be induced by 
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exposing vessels to negatively charged non-physiological surfaces such as glass 
and other silicates (Jesty, 2001). 
The extrinsic pathway is initiated by TF. TF activates fVII, forming the 
TF/fVIIa complex that induces the conversion of limited amounts of fIX to fIXa and 
catalyses the conversion of fX to fXa. The activation of fX marks the beginning of 
the common pathway. fXa forms a complex with fVa, phospholipids and calcium 
named prothrombinase complex, which activates thrombin by  prothrombin 
cleavage (Mann et al., 2003). Thrombin is involved in a large number of reactions 
within and outside the coagulation cascade. The major role of thrombin in blood 
coagulation is the conversion of fibrinogen into fibrin. It also contributes for fibrin 
polymerization and stabilization by activating fXIII. Thrombin further amplifies 
thrombin generation by proteolytic activation of fV, fVIII and fXI. Besides its action 
in the coagulation cascade, thrombin is also involved in inflammation and tissue 
repair (Thiagarajan and Narayanan, 2001). The fibrin network, obtained at the end 
of the coagulation cascade, together with red and white blood cells and platelets, 
forms the blood clot that avoids blood loss through the site of injury (Cotran et al., 
2000).  
Nowadays, this rigid division is less often used to represent the coagulation 
mechanism (Jesty, 2001; Mann et al., 2003). The contribution of the intrinsic 
pathway to haemostasis seems to be small. People who lack fXII are clinically 
normal, even to the extent of being able to undergo major surgery. In contrast, a 
deficiency in TF has never been observed in humans, and in studies with 
transgenic mice, more than 80% of TF knock out animals die from haemorrhage 
(Jesty, 2001). Thus, the extrinsic pathway seems to have an important role in 
coagulation cascade initiation, while the intrinsic pathway contributes to the 
generation of additional thrombin molecules by a positive feedback mechanism. 
These two pathways are interdependent, in contrast to what their rigid division 
suggests. (Thiagarajan and Narayanan, 2001). 
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1.2.1. Clotting regulation 
 
The coagulation cascade is tightly controlled by negative feedback 
mechanisms as well as by circulating and locally produced inhibitors (Figure 1). In 
this way, clot formation is restricted to the site of injury and the coagulation 
cascade is turned off once the blood clot is formed (Berkner, 2001). 
 When thrombin molecules diffuse away from the site of injury they are 
caught by thrombomodulin, present on the surface of uninjured endothelial cells. 
Thrombomodulin and thrombin form a complex that activates protein C, the major 
natural anticoagulant. Activated protein C binds to its cofactor protein S, produced 
by endothelial cells, and cleaves fVIIIa and fVa, shutting down the coagulation 
cascade. (Cotran et al., 2000) This negative feedback mechanism ensures a pulse 
of thrombin formation over the period during which cofactors are in their active 
state (Jesty, 2001). 
 There are also circulating inhibitors that shut off the activated clotting 
enzymes. Once the inhibitor-protease complex is formed it is rapidly removed from 
circulation and degraded (Berkner, 2001). Tissue factor pathway inhibitor (TFPI) 
blocks TF-fVII initiation of coagulation in a two-step mechanism: first, TFPI 
combines with fXa and then this complex inhibits TF-fVIIa complex. The need of 
fXa for inhibition of TF-fVIIa complex by TFPI allows the activation of significant 
amounts of fXa before inactivation of the TF-fVIIa complex (Jesty, 2001). Another 
circulating inhibitor is antithrombin III, a member of the serpin family of serine 
endopeptidase inhibitors (Rawlings et al., 2010). This inhibitor is present in plasma 
at levels largely exceeding those of its targets or their precursors (Jesty, 2001). 
Physiologically, antithrombin III inactivates thrombin and fXa and, to a lesser 
extent, factors IXa, XIa and XIIa (Bafunno and Margaglione, 2010). The inhibition 
mechanism used against thrombin is the best documented. Antithrombin III binds 
to thrombin, is cleaved but then traps thrombin in a complex (Berkner, 2001). The 
inhibition of clotting enzymes by antithrombin III is greatly increased by heparin, an 
highly sulfated polysaccharide (Jesty, 2001).  
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Figure 1 – Schematic representation of the coagulation cascade and its regulation. The 
coagulation cascade is initiated after a vessel injury when collagen or TF are exposed. The 
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successive activation of coagulation zymogens leads to the formation of thrombin, a proteinase that 
has a central role in coagulation and haemostasis. Thrombin cleaves fibrinogen into fibrin that, 
together with blood cells and platelets, forms the blood clot at the site of the injury. The coagulation 
cascade is tightly regulated in order to restrict clot formation to the site of injury and to turn off the 
cascade once the blood clot is formed. 
 
 
1.2.2. Clot stabilization and lysis 
 
The stability of the fibrin clot is determined by a delicate balance between 
coagulation and fibrinolysis. The fibrinolytic system is initiated after the formation 
of fibrin when both plasminogen and tissue-type plasminogen activator (tPA) bind 
to the fibrin surface to generate plasmin by proteolytic cleavage of plasminogen. 
The interactions between the lysine-binding sites of plasminogen and tPA and the 
C-terminal lysine residues of partially degraded fibrin result in the formation of a 
ternary complex and increase the catalytic efficiency of plasmin formation. Plasmin 
stimulates its own formation by generating new C-terminal lysine residues after 
fibrin cleavage (Figure 2). This positive feedback loop is stopped by plasminogen 
activator inhibitor (PAI), α2-antiplasmin and thrombin activatable fibrinolysis 
inhibitor (TAFI), thus protecting the fibrin clot against lysis (Bouma and Mosnier, 
2003; Cotran et al., 2000). 
PAI inhibits tPA interfering with plasminogen activation while α2-antiplasmin 
binds to plasmin forming an irreversible complex that is unable to lyse fibrin. 
Activated TAFI (TAFIa) inhibits fibrinolysis by removing C-terminal lysine and 
arginine residues from partially degraded fibrin, thereby lowering its binding 
capacity for plasminogen and inhibiting tissue plasminogen activator-mediated 
fibrin degradation. TAFI is activated by thrombin, but for this activation to occur 
higher concentrations of thrombin are required when compared to the amount 
necessary for fibrin formation. This fact combined with the short half-life of TAFI 
(about 10 minutes at 37ºC) suggest that regulation of its functional activity occurs 
most likely at the level of activation (Bouma and Mosnier, 2003). 
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Figure 2 – Clot stabilization and lysis. Fibrinolysis is initiated when plasminogen is cleaved to 
plasmin by tPA. Plasmin cleaves fibrin into soluble fibrin degradation products that contribute to the 
formation of new molecules of plasmin. This positive feedback loop is halted by PAI, α2-antiplasmin 
and TAFI (adapted from (Bouma and Mosnier, 2003)).  
 
 
1.3. Thrombosis 
 
 A deregulation in the processes involved in the maintenance of normal 
haemostasis can produce two pathologic situations: bleeding, when the 
deregulation leads to an inability to respond to a vessel injury, and thrombosis, 
when the haemostatic plug growth is not limited (Damjanov, 2000). There is also a 
pathology that combines bleeding and thrombosis named disseminated 
intravascular coagulation (DIC) (Cotran et al., 2000), in which the formation of 
disseminated small blood clots leads to a large consumption of platelets and 
coagulation proteins. With no machinery able to respond in case of injury, 
abnormal bleeding occurs. From this pathologies, thrombosis (in particular 
thromboembolism) is by far the major cause of morbility and mortality in western 
societies, largely due to the adopted life style and diet (Ajjan and Grant, 2006; 
Gross and Weitz, 2008). 
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1.3.1. Pathogenesis  
 
There are three predisposing conditions for the formation of pathological 
thrombi: endothelial cell injury, hemodynamic changes and hypercoagulability of 
the blood. These conditions, also known as the Virchow’s triad (Figure 3) can act 
independently to form a thrombus or can affect each other and have a cumulative 
effect (Cotran et al., 2000; Damjanov, 2000).  
 
 
 
Figure 3 – Representation of the Virchow’s triad.  
 
 
Endothelial injury leads to thrombus formation mainly in heart and arterial 
vessels. Sites for thrombus formation can include heart chambers (e.g. after an 
endocardic injury), ulcerated atherosclerotic plaques, inflammation sites or 
traumatic injury sites. Endothelial injury can also be produced by hemodynamic 
stress, radiation, bacterial toxins and smoking.  
Hemodynamic factors that promote coagulation are of two kinds: those that 
lead to turbulence and those that slow down the blood flow. The normal blood flow 
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is laminar meaning that the blood cells flow in the center of vascular lumen 
separated from the endothelium by acellular plasma that flows slower. Turbulence 
disturbs this normal flow and allows platelets to be exposed to the vessel wall and 
to discharge their granules as a result of mechanical stimulation. The turbulence 
also promotes damage of endothelial cells. On the other hand, slow blood flow 
promotes sedimentation of the cells and is also less efficient in washing away 
small thrombi than normal and more vigorous blood flow. 
The factors that lead to hypercoagulability of blood can be divided into 
primary and secondary factors. The primary factors arise from genetic 
modifications of coagulation cascade factors or of regulators that lead to abnormal 
or absence of function. The secondary factors are acquired and the most 
significant are cancer, tissue injury, DIC, chronic cardiac failure, pregnancy, oral 
contraceptives and smoking. 
 
 
1.3.2. Pathology  
 
In most situations the formation of small thrombi is not correlated with a 
pathologic situation because they are lysed. Large thrombi can be incorporated 
into the vessel wall or recanalized, and thus blood can keep flowing. However, if a 
thrombus cannot be firmly attached to the vessel wall, recanalized or dissolved 
two situations can occur: the thrombus can block the vessel in the same place 
where it was formed or it breaks off from the anchoring surface giving rise to an 
embolus. Thromboembolus is an embolus of thrombotic origin that flows with 
blood and blocks small vessels (Cotran et al., 2000; Damjanov, 2000).  
The occlusion of vessels leads to an interruption of the blood supply to an 
organ thus resulting in loss of function. This total occlusion can be observed in the 
histological section (Figure 4 A), where the whole diameter of a vessel is occupied 
by a thrombus. The presence of a vessel segment with no content confirms the 
absence of blood flow (Figure 4 A, thin arrow). 
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A prolonged insufficiency in blood supply can cause ischemic necrosis, 
named infarction. Every organ can be affected, resulting in different symptoms and 
conditions. The most severe thrombosis are those affecting the brain (Figure 4, B), 
heart or lungs, leading to irreversible damage and/or death (Cotran et al., 2000; 
Damjanov, 2000).  
 
 
 
Figure 4 – Thrombosis. A) Microthrombosis in a lung vessel. Histological section PAS stained 
amplified 150x of pulmonary parenchyma with a capillary containing a thrombus (large arrow). The 
thrombus is blocking the capillary avoiding the blood flow. Notice the appearance of capillary after 
the thrombus (thin arrow) (Riede and Werner, 2004) B) Saggital and cortical vein thrombosis. 
Coronal section of the brain showing a fatal infraction and liquefaction (arrow) of the brain 
substance drained by the cortical veins (Cooke and Stewart, 2004).  
 
 
1.4. Searching for therapeutic anticoagulants  
 
 Synthetic anticoagulants have been used to prevent and treat thrombosis in 
the venous and arterial circulation, including heart; however, they have well 
documented limitations. The increase of bleeding is the most common effect 
(Eikelboom and Hirsh, 2007) and some anticoagulants do not have a specific 
reversing agent, such as fondaparinux (Osinbowale et al., 2010). Interaction with 
other drugs and food were described for warfarin (Becattini et al., 2010). Some 
A B 
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anticoagulants, such as idraparinux and heparin, exert their inhibitory effect on the 
clotting enzymes indirectly via a potentiation of the inhibitory function of 
antithrombin, and thus, their inhibitory activity depends on the blood levels of this 
protein (Alban, 2008; Markwardt, 2003).   
The need to overcome all these limitations drives a continual and intense 
effort to develop new, efficient and safe anticoagulants.  
 
 
1.4.1. The best targets 
 
Thrombin plays a central role in the process of haemostasis and thrombosis 
and for this reason it has become the primary target for the development of 
anticoagulant agents (Markwardt, 2003). However, thrombin has a great number 
of important activities within and outside the haemostatic system. For this reason, 
the inhibition of thrombin could affect not only the procoagulant properties of this 
protease but also interfere with other thrombin activities. As a consequence, the 
efficacy and the safety of thrombin inhibitors is questionable (Ansell, 2007).  
Factor X is a good alternative to thrombin as a therapeutic target. Besides 
its position at the convergent point of the intrinsic and extrinsic pathways, in 
contrast to thrombin fXa has limited functions other than being the principal 
mediator of thrombin generation by prothrombinase activation. Furthermore, as the 
levels of serine proteinases are amplified at each step of the coagulation cascade, 
anticoagulants with target coagulation factors higher up than thrombin in the 
cascade, such fXa, are probably more effective than those directly targeting 
thrombin (Ansell, 2007).  
Thrombin and fXa have evolved from a common ancestral protease related 
to chymotrypsin. However, in contrast to chymotrypsin that cleaves almost any 
protein, thrombin and fXa as every other clotting enzyme, cleave only a few 
specific proteins. The ability of each proteinase to recognize its cofactor and to 
cleave specific proteins is dependent upon its structure (Berkner, 2001). For this 
reason, understanding the structure of thrombin and fXa, as well as the 
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interactions they establish with other proteins is of high practical importance for the 
design of specific therapeutic anticoagulants. In fact, the initial thrombin 
publications have produced enormous efforts in the pharmaceutical industry 
worldwide, aimed at rationally designing and elaborating specific direct thrombin 
inhibitors, that could help to prevent venous thrombotic events (Bode, 2005). 
 
 
1.4.1.1. Thrombin 
 
Thrombin (EC 3.4.21.5) is a trypsin-like member of the chymotrypsin family 
of serine proteases (Rawlings et al., 2010). The human α-thrombin molecule 
(Stubbs and Bode, 1993) is composed of a light chain (36 residues) and of a 
heavy chain (259 residues), covalently linked by a disulfide bridge (Cys1-Cys122). 
The catalytic triad of thrombin, composed of Ser195, His57 and Asp102, occupies 
the bottom of a rather narrow cleft sandwiched between two large loops “inserted” 
at positions 60 and 149. In spite of a neutral isoelectric point, the electrostatic 
surface of thrombin reveals two highly positive areas sandwiching the negative 
active-site between them. These two positive surface regions are named anion 
binding exosites I and II, and play major functional roles by regulating thrombin 
interactions with substrates, cofactors and natural inhibitors (described below). 
Anion exosite I and II are also known as fibrinogen-binding site and heparin-
binding site, respectively, showing their role in the specific interaction with 
fibrinogen and heparin (Figure 5, A). 
The complex structure of thrombin reflects the multifunctional character of 
this proteinase: thrombin is a procoagulant and anticoagulant and it also plays a 
role in cellular proliferation and inflammation (Thiagarajan and Narayanan, 2001). 
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1.4.1.2. Factor Xa 
 
Factor Xa (EC 3.4.21.6) is also a member of the trypsin-like serine 
proteinase family. As thrombin, fXa is composed of a light chain (16.2 kDa) and a 
heavy chain (42 kDa) linked together by a disulfide bond (Krupiczojc et al., 2008).  
The active site, by contrast, is more solvent-exposed, since the 60-loop and 149-
loop are 8 and 6-residues shorter respectively, when compared to thrombin. 
Factor Xa also possesses two charged surface regions that are topologically 
equivalent to the thrombin exosites (Figure 5, B). Similar to thrombin, the exosite II 
of fXa is positively charged and is involved in heparin binding. On the other hand, 
the exosite I of fXa is negatively charged and plays a role in the activation of fX by 
fIXa (Chen et al., 2004; Manithody et al., 2002). 
 
 
 
Figure 5 – Electrostatic surface potentials of human thrombin (A) and human fXa (B). The blue and 
red areas represent the positively and negatively charged surface, respectively. Notice the specific 
charge distribution of each proteinase and the accessibility of the active-sites (Corral-Rodríguez et 
al., 2009).  
 
 
A B 
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1.5. Coagulation inhibitors from haematophagous animals 
 
During evolution, while vertebrate animals developed a complex 
haemostatic system to prevent blood loss, blood-feeding animals evolved 
anticoagulant mechanisms to counteract the haemostatic response of their hosts 
in order to facilitate blood drawing, storage and digestion. These anticoagulant 
mechanisms interfere with fibrinolysis, platelet aggregation and blood coagulation 
(Urata et al., 2003). The blood coagulation inhibitors identified in blood-feeding 
animals seem to be directed mainly to thrombin and its activator fXa. Unlike 
physiological inhibitors of blood coagulation proteinases, which are mainly of the 
serpin and Kunitz families, large molecular diversity is observed in the coagulation 
inhibitors from haematophagous animals (Koh and Kini, 2009). Although a number 
of natural inhibitors from haematophagous animals have been described, only a 
few have been fully characterised, and even fewer have been studied from a 
structural view-point.  
Because of its special role in blood coagulation, thrombin has become the 
most attractive target for potential therapies against thrombosis. Consequently, 
special attention was dedicated to the study of haematophagous-derived thrombin 
inhibitors. To date, only six thrombin inhibitors were structurally characterised 
revealing six different inhibition strategies in a wide variety of structural scaffolds 
(Fuentes-Prior et al., 1997; Grütter et al., 1990; Macedo-Ribeiro et al., 2008; 
Richardson et al., 2000; Rydel et al., 1990; Van de Locht et al., 1995; Van de 
Locht et al., 1996). 
 
 
1.5.1. Thrombin inhibitors 
 
The thrombin inhibitor hirudin, isolated from the leech Hirudo medicinalis, is 
the best studied natural thrombin inhibitor (Grütter et al., 1990; Markwardt, 1970; 
Rydel et al., 1990; Stone and Hofsteenge, 1986). The N-terminal domain of hirudin 
folds into a globular unit stabilised by three disulfide bridges and the C-terminal 
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domain shows an extended conformation. During thrombin inhibition, the three N-
terminal residues bind to an hydrophobic pocket on the active site of thrombin in a 
non-canonical manner, while the C-terminal region, rich in acidic residues, 
interacts with exosite I (Figure 6, A). Hirudin, the most potent thrombin inhibitor 
known so far (Ki = 22x10
-15 M), has been used as a model for the development of 
anticoagulant inhibitors. Nowadays, structural variants of hirudin are produced as 
recombinant proteins (leupirudin and desirudin) for therapeutic use. However, they 
have limitations: bleeding, lack of a specific antidote and risk of immunoresponse 
(Greinacher and Warkentin, 2008).  
Another member of the hirudin family is haemadin (Rawlings et al., 2010). 
Although hirudin and haemadin share low sequence similarity, they display a 
common three-dimensional structure: a globular N-terminal stabilised by three 
disulfide bridges with an extended acidic tail. The inhibition of thrombin by 
haemadin, with an inhibition constant of 2.4x10-13 M, involves the binding of the 
three N-terminal residues of haemadin to the active site of thrombin, similar to 
hirudin, and the interaction of the C-terminal tail with the exosite II instead of the 
exosite I (Figure 6, B) (Richardson et al., 2000). 
The only thrombin Kazal-type inhibitor structurally characterized is rhodniin, 
isolated from Rhodnius prolixus. Rhodniin is composed by two Kazal-type domains 
and exhibits an inhibition constant of about 2x10-13 M (Friedrich et al., 1993). The 
first domain canonically binds to the thrombin active site and the second interacts 
with the exosite I (Figure 6, C) (Van de Locht et al., 1995). 
Triabin, isolated from Triatoma pallidipennis (Noeske-Jungblut et al., 1995) , 
shows no similarity with any other inhibitor known, giving name to the triabin family 
(Rawlings et al., 2010). Its structure shows an eight-stranded β-sheet, which is 
smoothly rolled and annealed at both edges forming a slightly flattened and 
conical β-barrel with the overall appearance of a calyx (Fuentes-Prior et al., 1997). 
The interaction of triabin with the exosite I of thrombin effectively blocks thrombin’s 
cleavage of physiological substrates (Figure 6, D). The inhibition constant found 
for triabin was 3x10-12 M (Noeske-Jungblut et al., 1995). 
Ornithodorin and boophilin are both from the BPTI-Kunitz family. 
Ornithodorin (Van de Locht et al., 1996) was isolated from Ornithodorus moubata 
Characterization of trypsin inhibition by boophilin 
 
 
30 
 
and is a potent thrombin inhibitor (Ki= 1x10
-12 M). It is composed of two distorted 
Kunitz modules:  the highly acidic C-terminal domain binds to the exosite I of 
thrombin and the first N-terminal residues interact with the active site (Figure 6, E). 
Boophilin (Macedo-Ribeiro et al., 2008) was isolated from Boophilus microplus, 
recently reclassified as Rhipicephalus microplus (Barker and Murrell, 2002).  This 
inhibitor is composed of two canonical Kunitz-type domains. During thrombin 
inhibition, the N-terminal residues of boophilin bind across thrombin’s active site 
cleft in a parallel, hirudin-like manner while the C-terminal domain interacts with 
thrombin’s exosite I (Figure 6, F). Boophilin exhibits an inhibition constant of 
1.8x10-9 M against thrombin. 
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Figure 6 – Interactions between thrombin and six of its inhibitors. Thrombin is represented by its 
electrostatic surface potential while inhibitors are shown as orange ribbons. A) Hirudin-thrombin 
complex (PDB: 1HRT); B) Haemadin-thrombin complex (PDB: 1E0F); C) Rhodniin-thrombin 
complex (PDB: 1TBQ); D) Triabin-thrombin complex (PDB: 1AVG); E) Ornithodorin-thrombin 
complex (PDB: 1TOC); F) Boophilin-thrombin complex (PDB: 2ODY). 
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1.5.1.1. Boophilin 
  
There are two described variants of boophilin: isoform H2 and isoform G2. 
The mRNA encoding for the mature protein of each isoform has eight nucleotide 
differences, four of which result in amino acids exchanges. However, these 
substitutions are conservative: in the N-terminal domain, the aspartic acid present 
at position 66 of isoform G2 is replaced by a glutamic acid in isoform H2; in the 
linker region Ser78 and Gly82 of isoform G2 are substituted in isoform H2 by an 
asparagine and a serine, respectively; and in the C-terminal domain, Arg110 of 
isoform G2 is replaced by a glutamine in isoform H2 (Figure 7) (Macedo-Ribeiro et 
al., 2008). Both isoforms have a molecular weight of about 13.9 kDa and an 
isoelectric point of 4.3. 
 
 
 
Figure 7 – Amino acid alignment between the two isoforms of boophilin. The signal peptide is 
shadowed in grey. The amino acid differences between both isoforms are highlighted in red. 
 
 
Boophilin inhibits thrombin, the central proteinase of the coagulation 
cascade (Macedo-Ribeiro et al., 2008). From a therapeutic point of view, boophilin 
could be used not only as an anticoagulant but also as a model for the design of 
           1        10        20        30        40        50        60 
           |        |         |         |         |         |         |        
    H2     MKCIILLAVLGTAFAQRNGFCRLPADEGICKALIPRFYFNTETGKCTMFSYGGCGGNENN 
    G2     MKYLILLAVLGTAFAQRNGFCRLPADEGICKALIPRFYFNTETGKCTMFSYGGCGGNENN 
        
 
                    70        80        90        100       110       120 
                    |         |         |         |         |         | 
    H2     FETIEECQKACGAPERVNDFESADFKTGCEPAADSGSCAGQLERWFYNVQSGECETFVYG 
    G2     FETIEDCQKACGAPERVSDFEGADFKTGCEPAADSGSCAGQLERWFYNVRSGECETFVYG 
        
 
                    130       140 
                    |         | 
    H2     GCGGNDNNYESEEECELVCKNM 
    G2     GCGGNDNNYESEEECELVCKNM 
        
 
Characterization of trypsin inhibition by boophilin 
 
 
33 
 
synthetic anticoagulant drugs. On the other hand, thrombin inhibitors are critical for 
haematophagous animals during feeding and digestion. For this reason it has been 
proposed that inhibitors targeting thrombin, such as boophilin, could be used as 
targets for the control of pathogen-transmitting parasites (Wikel and Bergman, 
1997). 
 
 
1.5.1.1.1. Inhibitor of clot formation 
 
In vitro, boophilin is able to inhibit several serine proteases, including 
thrombin, trypsin, plasmin and urokinase-type plasminogen activator. Despite the 
ability to inhibit at least these proteases, boophilin is specially active against 
thrombin and trypsin. The activity of boophilin against these two proteases is 
significantly reduced in absence of the N-terminal domain (Macedo-Ribeiro et al., 
2008). 
The crystallographic structure of the thrombin-boophilin complex shows that 
this inhibitor is composed by two canonical BPTI-Kunitz domains connected by a 
10-residue linker. In spite of the presence of a reactive site loop in the N-terminal 
domain, boophilin inhibits thrombin according to a non-canonical mechanism, in 
which the N-terminal Arg17 blocks the active site of thrombin while the negatively 
charged surface of the C-terminal domain establishes electrostatic and 
hydrophobic interactions with the exosite I of thrombin (Figure 8) (Macedo-Ribeiro 
et al., 2008). 
The most interesting feature about boophilin is that thrombin-bound 
boophilin retains the capability to interact with a trypsin-like serine proteinase. The 
presence of an alanine at the P1 position of the C-terminal domain of boophilin 
strongly disfavours it canonical binding to a trypsin-like protease and the ability of 
the isolated N-terminal domain to inhibit trypsin suggests that boophilin inhibits a 
subset of trypsin-like serine proteinases according to a canonical mechanism with 
the Lys31 occupying the S1 pocket of the bound enzyme. In fact, the structure of 
the thrombin-boophilin complex shows that Lys31 remains completely accessible 
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for interaction with an additional proteinase (Figure 8). (Macedo-Ribeiro et al., 
2008).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Boophilin in complex with thrombin (PDB: 2ODY). Thrombin is represented by its 
electrostatic surface potential while boophilin is shown as an orange ribbon. Boophilin is composed 
of two canonical BPTI-Kunitz domains. The presence of a lysine at the P1 position of the N-
terminal domain of boophilin favours it canonical binding to a trypsin-like proteinase.  
 
 
In vivo, it is possible that besides inhibiting thrombin, boophilin targets 
another trypsin-like serine proteinase of the coagulation cascade. Meizothrombin 
is an intermediate during the prothrombin activation by the prothrombinase 
complex (fXa-fVa).  If boophilin is also able to inhibit meizothrombin, that already 
has the active site and exosite I formed, fXa seems to be the most attractive 
candidate because of its physical proximity. This would result not only in thrombin 
inhibition, but also in the impairment of thrombin generation, making boophilin a 
good model for the design of new therapeutic anticoagulants. However, in vitro fXa 
is only marginally inhibited by free boophilin. It is possible that the formation of the 
ternary complex depends on the proper orientation of both membrane-bound 
serine proteinases, and probably requires additional boophilin-fVa interactions 
(Macedo-Ribeiro et al., 2008). This strategy is already used by some inhibitors, 
    60-loop 
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  Ala99 
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such as TFPI. The TFPI inhibits fVIIa using its first Kunitz domain, but only after its 
second Kunitz domain bound fXa (Broze, 1995). 
 
 
1.5.1.1.2. Target for Rhipicephalus microplus control 
 
Boophilin is produced by the cattle tick Rhipicephalus microplus, the major 
ectoparasite affecting livestock in America, Asia, Africa and Oceania. Besides 
being the vector of Babesia spp and Anaplasma spp, this blood-sucking parasite 
causes significant economic impact due to both blood and milk losses and leather 
damage. The enormous economic losses caused by this parasite could be 
minimized by the control of tick populations down to acceptable levels. Usually, 
tick control is performed with acaricides, however, the improper use of these 
substances has increased the incidence of acaricide-resistant ticks, besides 
increasing the occurrence of environmental and food contamination. Thus, the 
development of new control strategies is necessary (Parizi et al., 2009). 
It has been proposed that preventing blood feeding of pathogen-transmitting 
parasites by interfering with specific inhibitors of haemostasis could provide novel 
approaches for improving human and animal health (Wikel and Bergman, 1997). 
Boophilin is the best studied and the most potent coagulation inhibitor from 
Rhipicephalus microplus known (Ciprandi et al., 2006; Horn et al., 2000; Macedo-
Ribeiro et al., 2008; Ricci et al., 2007) and, for this reason, boophilin seems to be 
the best target for the development of new anti-Rhipicephalus microplus vaccines. 
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1.6. Objectives 
 
Boophilin is a serine endopeptidase inhibitor able to inhibit in vitro thrombin 
and trypsin at the same time. This ability is unique between the thrombin inhibitors 
described to date and suggests that boophilin uses two different inhibition 
mechanisms. Up to now, only the inhibition mechanism used against thrombin was 
described. In vivo, the second inhibition mechanism is probably used against a 
(non-thrombin) trypsin-like serine proteinase from the coagulation cascade, such 
as fXa. This ability would result not only in thrombin inhibition but also in the 
impairment of thrombin generation, making boophilin a good model for the design 
of new anticoagulant drugs. This thesis proposes to clarify this second inhibition 
mechanism by studying the trypsin-boophilin complex.  
The inhibition of trypsin by the isolated C-terminal domain (second domain) 
of boophilin is only observed when it is in large excess over the protease. 
Moreover, the presence of a lysine in the reactive-loop of the N-terminal domain 
(first domain) of boophilin strongly suggests that trypsin inhibition is achieved by 
this domain (Macedo-Ribeiro et al., 2008). We propose to clarify the contribution of 
each isolated domain by comparing the inhibition constants between full-length 
boophilin and its isolated first domain. However, to understand the inhibition 
mechanism used by boophilin against trypsin, additional studies are necessary. 
The interaction between proteins has been studied by X-ray crystallography, 
which allows the visualization of the complex at atomic or near atomic level. As the 
name suggests, for the application of X-ray diffraction, the protein must be first 
crystallized. The crystallization has become the primary obstacle in X-ray 
crystallography since protein crystallization is highly affected by their dynamic 
structure (McPherson, 2004). Assuming that the second domain does not 
participate in the inhibition of trypsin, the complex composed by full-length 
boophilin and trypsin would be very flexible and hard to crystallize. If boophilin 
inhibits trypsin only by its first domain the complex composed by the isolated first 
domain and trypsin would be a good model to study the inhibition mechanism and 
would also probably crystallize. However, it is first necessary to confirm that the 
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isolated first domain has a conformation similar to the first domain of the full-length 
boophilin. We propose to crystallize and determine the structure of the isolated first 
domain of boophilin by X-ray crystallography.  
If the crystallographic structure of the isolated first domain shows a 
conformation similar to the first domain of full-length boophilin, we propose to 
crystallize the complex composed by the isolated first domain and trypsin and to 
determine it crystallographic structure.  
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2.1. Materials 
 
Bovine pancreatic trypsin, Glycine max trypsin inhibitor, Glycine max 
trypsin-chymotrypsin inhibitor, BSA, NPGB, primers (3’AOX1 and 5’AOX1), phenol-
chloroform-isomyl alcohol, cyanoborohydride solution, 2-mercaptoethanol, 
benzamidine, TEMED, bromophenol blue, glycine, calcium chloride, BIS-TRIS, 
potassium phosphate monobasic, potassium phosphate dibasic, potassium 
acetate, manganese (II) chloride, sodium acetate, sodium cacodylate, sodium 
oxamate, Triton X-100, ammonium sulfate, MOPS, methanol, tryptone and the 
glycerol used for crystallography were acquired from Sigma-Aldrich Química S.A. 
(Sintra, Portugal). PEG 1000, PEG 3350, PEG 8000, MPD, sodium carbonate, 
myo-inositol, biotin, rubidium chloride and potassium hydroxide were obtained from 
Fluka, as part of Sigma-Aldrich Química S.A. (Sintra, Portugal). Magnesium sulfate 
and sodium citrate were acquired from Riedel-de-Haën, distributed by Sigma-
Aldrich Química S.A. (Sintra, Portugal). Sodium chloride, yeast extract, Tris, 
sodium formate, lithium sulfate monohydrate, sodium azide, glacial acetic acid, 
hydrochloric acid, dextrose, EDTA, potassium chloride, magnesium chloride, MES, 
sodium phosphate dibasic, sodium phosphate monobasic and sodium hydroxide 
were purchase from Merck, distributed by VWR (Carnaxide, Portugal). Ethanol was 
purchased from Aga (Porto, Portugal). Imidazole was acquired from USB 
Corporation, distributed by Isogen Life Science (Barcelona, Spain). Agar was 
obtained from Liofilchem and ethidium bromide solution was acquired from 
AppliChem, both distributed by Frilabo (Maia, Portugal). The glycerol used in 
culture media was obtained from Panreac (Amadora, Portugal). BactoTM peptone 
was purchased from BD Biosciences, distributed by ENZIfarma S.A. (Oeiras, 
Portugal). Sodium dodecylsulfate (SDS), acrylamide solution, APS and Poly-Prep® 
Column were obtained from Bio-rad (Amadora, Portugal). PageBlueTM stain, Pfu 
polymerase, Pfu polymerase buffer, dATP, dTTP, dCTP, dGTP and 6x Orange 
Loading Dye were obtained from Fermentas, distributed by Bioportugal (Porto, 
Portugal). NZYMiniprep Kit was obtained from NZYTech (Lisboa, Portugal). 
QIAquick® PCR Purification Kit and QIAquick® Gel Extraction Kit were acquired 
from QIAGEN, distributed by Izasa Portugal (Carnaxide, Portugal). CNBr-activated 
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Sepharose 4B, Mono Q and Superdex 75 columns and bovine thrombin were 
obtained from GE Healthcare (Carnaxide, Portugal). AminoLink Plus Coupling 
Resin was purchased from Thermo Scientific Pierce, distributed by Dagma Lda 
(Carcavelos, Portugal). Agarose and ZeocinTM were purchased from Invitrogen Life 
Technologies (Barcelona, Spain). The chromogenic substrate Bz-Phe-Val-Arg-pNA 
was purchased from Bachem (Weil am Rhein, Germany). Chromozym® TH (Tos-
Gly-Pro-Arg-pNA) was purchased from Roche (Amadora, Portugal). Crystal 
Screen, Crystal Screen 2, PEG-Ion and Index were obtained from Hampton 
Research (Aliso Viejo, California). Proplex, Morpheus and JCSG-plus were 
acquired from Molecular Dimensions (Newmarket, United Kingdom).  
 
 
2.2. Preparation of Escherichia coli DH5α competent cells 
 
Escherichia coli DH5α cells were grown in LB agar plates (Appendix I, a, i) 
at 37 ºC overnight. A single colony was used to inoculate 10 ml of LB medium 
(Appendix I, a, i). The culture was grown at 37 ºC with shaking (180 rpm) to an 
optical density (OD) of 0.3 at 550 nm. The biomass was then amplified by adding 4 
ml of this culture to 100 ml of LB medium and incubating in the above conditions 
until an OD of 0.3 at 550 nm was reached. The culture was then incubated on ice 
for 5 minutes followed by centrifugation at 1000 g for 5 minutes at 4 ºC. The 
supernatant was discarded and the pellet was gently resuspended in 20 ml of ice-
cold TFB I (Appendix I, b, i). After centrifugation at 1000 g and 4 ºC for 5 minutes, 
the new supernatant was rejected and the pellet suspended in 2.5 ml of ice-cold 
TFB II (Appendix I, b, ii). The cell suspension was incubated on ice for 5 minutes, 
aliquoted into ice-cold microcentrifuge tubes, frozen in liquid nitrogen and stored at 
-80 ºC. 
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2.3. Bacterial transformation 
 
Fifty microlitres of E. coli DH5α competent cells prepared as described in 
section 2.2 were thawed on ice and 200 ng of pPICZαB (Appendix III) containing 
the cDNA for full-length boophilin (D1D2) or for its first domain (D1) was added. 
The mixture was incubated on ice for 30 minutes and heat-shocked at 42 ºC for 30 
seconds. The mixture was incubated on ice for 2 minutes before adding 600 μl of 
SOC medium (Appendix I, a, ii). Cells were recovered at 37 ºC for 1 hour with 
shaking (180 rpm). For transformant selection two hundred microlitres of the 
culture were spread on Low Salt LB agar plates (Appendix I, a, iii) containing 25 
μg/ml of ZeocinTM (Invitrogen). A low salt concentration is required for the 
transformant selection with ZeocinTM, since a salt concentration above 90 mM 
inhibits the drug. The plates were incubated at 37 ºC overnight. A negative control 
was performed in parallel, without plasmid DNA addition. 
 
 
2.4. Isolation and purification of plasmid DNA 
 
A single colony of E. coli DH5α transformed with pPICZαB-D1D2 or 
pPICZαB-D1 was grown at 37 ºC overnight with shaking (180 rpm) in 10 ml of Low 
Salt LB containing 25 μg/ml of ZeocinTM. Each vector was purified using the 
NZYMiniprep Kit (NZYTech). The overnight culture was centrifuged at 4000 g for 
10 minutes at room temperature and the supernatant was discarded. The cell 
pellet was resuspended in Buffer A1 and lysed with 250 µl of lysis buffer (Buffer 
A2). After mixing by gently inverting the tubes 8 times, the mixture was incubated 
at room temperature for 4 minutes. Three hundred microlitres of neutralization 
buffer (Buffer A3) were added and mixed by gently inverting the tubes 8 times. The 
solution was then centrifuged for 10 minutes at 16000 g and the supernatant 
obtained was loaded onto the NZYTech spin column already placed in a 2 ml 
collecting tube. After centrifugation at 16000 g for 1 minute the flow-through was 
discarded. The column membrane was washed in two steps  by centrifugation for 1 
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minute at 16000 g with 500 µl of Buffer AW pre-warmed at 50 ºC followed by 600 
µl of Buffer A4. An additional centrifugation at 16000 g for 2 minutes was 
performed in order to remove all ethanol from the column membrane. The 
NZYTech spin columns were placed into clean 1.5 ml microcentrifuge tubes. Thirty 
microlitres of sterile water were loaded onto the column and incubated for 1 minute 
at room temperature. DNA was collected by centrifugation at 16000 g for 1 minute. 
The eluted DNA was quantified by measuring the absorbance at 260 nm and the 
quality was assessed by the ratio between the absorbance at 260 nm and 280 nm 
and at 260 nm and 230 nm. This analysis was performed on a NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific). 
 
 
2.5. Genomic DNA extraction 
 
Ten microlitres of each glycerol stock containing Pichia pastoris cells 
transformed with pPICZαB-D1 or pPICZαB-D1D2 were grown in 10 ml of YPD 
medium (Appendix II, a, i) containing 100 μg/ml of ZeocinTM at 28 ºC and 220 rpm 
to an OD of 1.5 at 600 nm. After reaching the desired OD, the culture was 
centrifuged at 1200 g for 10 minutes at room temperature. The supernatant 
obtained was rejected and the pellet was resuspended in 500 µl of sterile water. 
After transferring to a microcentrifuge tube, the suspension was centrifuged at 
16000 g for 5 minutes at room temperature.  The supernatant obtained was 
rejected and the cell pellet was resuspended in 200 µl of lysis buffer (Appendix II, 
b, i). Three hundred milligrams of glass spheres (Ø 0.5 mm) and 200 µl of phenol-
chloroform-isoamyl alcohol mixture were added and then all the components were 
mixed by vortexing at high speed for 3 minutes at room temperature. Two hundred 
microlitres of TE buffer (10 mM pH 8.0, 1 mM EDTA) were added and the mixture 
was mixed by vortexing. After centrifugation at 16000 g for 5 minutes at room 
temperature, the aqueous phase (upper phase) was transferred to a clean 
microcentrifuge tube. Nucleic acids were precipitated by adding 1 ml of 100% 
ethanol and mixing by inverting the tube. After centrifugation at 16000 g for 3 
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minutes at room temperature, the supernatant was rejected and the pellet 
resuspended in 400 µl of TE buffer. To remove RNA, 30 µg of RNAse A were 
added and incubated for 5 minutes at 37 ºC followed by precipitation of genomic 
DNA with 10 µl of 3 M sodium acetate and 1 ml of 100% ethanol. After 
centrifugation at 16000 g for 3 minutes at room temperature the supernatant was 
rejected and the pellet was air-dried at room temperature. The genomic DNA was 
resuspended in 50-100 µl of sterile water until complete dissolution. The DNA was 
quantified by measuring the absorbance at 260 nm and the quality was analysed 
by the ratio between the absorbance at 260 nm and 280 nm and at 260 nm and 
230 nm.  The integrity of genomic DNA was confirmed by DNA electrophoresis as 
described in section 2.9.  
 
 
2.6. Polymerase chain reaction 
 
The sequences coding for the D1D2 or the D1 integrated in the genomic 
DNA of Pichia pastoris cells were amplified by PCR. The reaction mixture 
containing Pfu buffer (20 mM Tris-HCl pH 8.8 at 25 ºC, 10 mM (NH4)2SO4, 10 mM 
KCl, 0.1 mg/ml BSA, 0.1% (v/v) Triton X-100, 2 mM MgSO4) (Fermentas), 0.2 mM 
of each dNTP (dATP, dCTP, dGTP, dTTP), 0.5 μM of 3’AOX1 primer (5´-
GCAAATGGCATTCTGACATCC-3´), 0.5 μM 5’AOX1 primer (5´-
GACTGGTTCCAATTGACAAGC-3´) and 2 U Pfu DNA polymerase (Fermentas) 
were added to about 1 μg of genomic DNA to a final volume of 50 µl. The cDNA 
was amplified by 30 cycles of denaturation at 95 ºC for 30 seconds, annealing at 
57 ºC for 30 seconds and extension at 72 ºC for 2 minutes preceded by a initial 
denaturation step at 95 ºC for 3 minutes and followed by a final extension step at 
72 ºC for 15 minutes. The PCR product obtained after amplification of D1D2 cDNA 
was re-amplified by a new PCR. The PCR product was first purified as described in 
section 2.7 and then 36 ng of purified PCR product were added to the reaction 
mixture to a final volume of 50 µl. The amplification reaction was performed in the 
same conditions as described previously. The PCR product was analysed by DNA 
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gel electrophoresis (section 2.9), purified (section 2.7 and 2.8) and sequenced 
(section 2.10). 
 
 
2.7. Purification of the PCR product  
 
The PCR product was purified using the QIAquick® PCR Purification Kit 
(QIAGEN). Two hundred microlitres of binding buffer (Buffer PB) were added to 40 
µl of PCR product and mixed by gently pipetting up and down. Once the colour of 
the mixture had turned violet, 10 µl of 1 M sodium acetate pH 4.1 were added and 
the sample was applied to a QIAquick spin column already placed into a 2 ml 
collection tube. After centrifugation at 16000 g for 60 seconds at room 
temperature, the flow-through was discarded and the column was washed with 750 
µl of Buffer PE by repeating the previous centrifugation. The flow-through was 
discarded and the column centrifuged for an additional 1 minute to remove all 
traces of ethanol. The column was placed in a clean 1.5 ml microcentrifuge tube 
and 30 µl of sterile water were added to the center of the QIAquick membrane. 
After incubation for 1 minute at room temperature, the DNA was eluted by 
centrifugation at 16000 g for 1 minute at room temperature. The eluted DNA was 
quantified by measuring the absorbance at 260 nm and the quality was assessed 
by the ratio between the absorbance at 260 nm and 280 nm and at 260 nm and 
230 nm. This analysis was performed on a NanoDrop ND-1000 Spectrophotometer 
(Thermo Scientific). 
 
 
2.8. Purification of DNA from agarose gel 
 
The PCR product obtained after the second amplification of D1D2 cDNA 
was separated from contaminants by agarose gel electrophoresis. The band 
containing the D1D2 cDNA was excised from the gel with a sterile scalpel blade 
under UV light and the cDNA was purified using the QIAquick® Gel Extraction Kit 
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(QIAGEN). The gel slice was weighed and the agarose dissolved in 3 gel volumes 
(considering 1 µl = 1 μg) of solubilization buffer (Buffer QC) at 50 ºC for 10 
minutes. During this incubation, the sample was mixed by vortexing every 3 
minutes. After dissolution, 1 gel volume of isopropanol was added to the sample 
and mixed by inverting the tube. The sample was then applied to a QIAquick spin 
column already placed in a 2 ml collection tube. The column was centrifuged at 
16000 g for 1 minute and the flow-through was discarded. In order to remove all 
traces of agarose, the column was washed with 0.5 ml of Buffer QG by 
centrifugation at 16000 g for 1 minute. The column was then incubated with 0.75 
ml of Buffer PE for 2 minutes at room temperature. After centrifugation at 16000 g 
for 1 minute the flow-through was discarded and the column centrifuged for an 
additional 1 minute to remove all ethanol from the column membrane. The column 
was placed into a sterile 1.5 ml microcentrifuge tube and incubated with 30 µl of 
sterile water for 1 minute at room temperature, and then centrifuged at 16000 g for 
1 minute at room temperature to collect the purified DNA. The eluted DNA was 
quantified by measuring its absorbance at 260 nm and its quality was assessed by 
the ratio between the absorbance at 260 nm and 280 nm and at 260 nm and 230 
nm. This analysis was performed on a NanoDrop ND-1000 Spectrophotometer 
(Thermo Scientific). 
 
 
2.9. DNA electrophoresis 
 
Genomic DNA and PCR products were analysed on a 2% agarose gel 
containing 0.2 μg/ml of ethidium bromide. Samples were prepared by adding 1/6 
sample volume of 6x Orange DNA Loading Dye (10 mM Tris-HCl pH 7.6, 0.15% 
orange G, 0.03% xylene cyanol FF, 60% glycerol and 60 mM EDTA) (Fermentas). 
The agarose gels (50 ml) were run at 100 V in TAE buffer (0.2 M Tris, 0.571% 
glacial acetic acid, 5 mM EDTA). 
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2.10. DNA sequence analysis 
 
The cDNA for D1D2 and D1 cloned into pPICZαB or amplified from the 
genomic DNA of P. pastoris were analysed by DNA sequencing using 5’AOX1 (5’-
GACTGGTTCCAATTGACAAGC-3’) as primer (Eurofins MWG, Germany). The 
nucleotide sequences obtained for the plasmids were translated and aligned with 
both boophilin isoforms (GenBank numbers CAC82583.1 and CAC82582.1). The 
nucleotide sequences obtained for the genomic DNA were translated and aligned 
with the amino acid sequences obtained for the plasmids. All alignments were 
performed using the ClustalW tool (Thompson et al., 1994) 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html). 
. 
 
2.11. Expression of D1 or D1D2 
 
Pichia pastoris KM71H cells transformed with pPICZαB coding for D1D2 or 
D1 fused to a N-terminal signal peptide (α-factor) were grown in YPD agar plates 
(Appendix II, a, i) containing 100 μg/ml of ZeocinTM for 2 days. Ten millilitres of 
BMGY (Appendix II, a, ii) were used to grow one colony at 29 ºC and 220 rpm to 
an OD of 2-6. The cellular mass was amplified by adding the previous culture to 1 l 
of BMGY and growing in the same conditions to an OD of 2-6. To induce 
expression, the pellet obtained after centrifugation of the culture was resuspended 
in 200 ml BMMY (Appendix II, a, iii). The cells were incubated at 29 ºC and 220 
rpm for 5 days. Every 24 hours 1 ml of 100% methanol was added to the culture. 
Since both recombinant proteins were secreted, cells were harvested by 
centrifugation at 10000 g for 5 minutes at room temperature and the supernatant 
was saved. The expression was confirmed by SDS-PAGE analysis (sections 2.15) 
and in vitro activity assays (2.16).  
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2.12. Purification of D1D2 
 
D1D2 was first purified by affinity chromatography in an immobilized-trypsin 
column. This column was prepared as described below. 
 
 
2.12.1. Preparation of the affinity column 
 
An immobilized-trypsin affinity column was prepared by coupling bovine 
pancreatic trypsin (Sigma) to CNBr-activated Sepharose 4B (GE Healthcare). This 
medium was supplied lyophilized in the presence of additives. In order to remove 
the additives, 5 g of lyophilized powder were resuspended in 100 ml of 1 mM HCl 
and washed for 20 minutes in 900 ml of the same solution on a sintered glass filter 
(porosity G3). The swollen medium was washed with 200 ml of 0.1 M NaHCO3 pH 
8.3, 0.5 M NaCl (coupling solution). Seven hundred and fifty milligrams of trypsin 
were dissolved in 12 ml of coupling buffer (at this stage 10 µl of the mixture were 
saved for protein quantification by measuring the absorbance at 280 nm). Two 
millilitres of 200 mM benzamidine solution were prepared in coupling buffer and 
added to the 12 ml of trypsin solution. The trypsin-benzamidine solution was 
incubated with the medium at 4 ºC overnight. The suspension was filtered on a 
sintered glass filter (porosity G3) and the flow-through was collected. The 
benzamidine present in the flow-through was eliminated by 3 cycles of dialysis 
each against 100 volumes of coupling buffer at 4 ºC. After dialysis the trypsin 
present in the flow-through was quantified by measuring the absorbance at 280 
nm. The medium was washed with 100 ml of coupling buffer to remove the excess 
of trypsin. The remaining reactive groups of the medium were blocked by 
incubating with 50 ml of ethanolamine pH 8.0 for 2 hours at room temperature with 
end-over-end rotation. The medium was washed with 3 cycles of alternating pH. 
Each cycle included a wash with 50 ml of 0.1 M sodium acetate pH 4.0 containing 
0.5 M NaCl followed by 50 ml of 0.1 M Tris-HCl pH 8.0 containing 0.5 M NaCl. 
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The coupling efficiency was determined by subtracting the amount of trypsin 
present in the dialysed flow-through to the total protease in the trypsin solution. 
The percentage of active trypsin coupled to the medium was also quantified in 
order to determine the effective binding capacity. One millilitre of medium was 
loaded into a Poly-Prep® Column (Bio-Rad) and equilibrated with 20 ml of 50 mM 
Tris-HCl pH 8.0, 150 mM NaCl (binding buffer). Twelve milligrams of Glycine max 
trypsin-chymotrypsin inhibitor (Sigma) were dissolved in binding buffer and added 
to the column. The column was washed with 30 ml of binding buffer and bound 
material was eluted with 8 ml of 0.5 M KCl pH 2.0. One millilitre fractions were 
collected and their pH neutralized by adding 50 µl of 1 M Tris (pH not adjusted). 
The eluted material was quantified by measuring the absorbance at 280 nm. The 
amount of trypsin inhibitor present in the eluted material was used to quantify the 
binding capacity of the column. 
 
 
2.12.2. Purification of D1D2 
 
The supernatant obtained after D1D2 expression was filtered (0.45 µm 
pore) and applied to the immobilized-trypsin affinity column prepared as described 
before, previously equilibrated with at least 20 column volumes of 0.1 M Tris-HCl 
pH 8.0. The column was washed with at least 20 column volumes of 0.1 M Tris-
HCl pH 8.0 and bound proteins were eluted by competition with 4 column volumes 
of 1 M benzamidine in the same buffer. The benzamidine present in the eluted 
material was eliminated by 3 cycles of dialysis each against 100 sample volumes 
of 20 mM Tris-HCl pH 8.0, 150 mM NaCl at 4 ºC. Purified material was analysed 
by SDS-PAGE and by activity assays (see section 2.14 and 2.15) before the 
second purification step. The dialysed material was diluted 10 times with 20 mM 
Tris-HCl pH 8.0 and applied to a MonoQ column (5 x 50 mm) (Amersham) pre-
equilibrated with at least 5 column volumes of the same buffer. The column was 
washed with 10 column volumes of 20 mM Tris-HCl pH 8.0, and bound proteins 
were eluted with a linear gradient from 0 to 1.0 M NaCl in the same buffer. The 
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absorbance at 214 and 280 nm was monitored on an ÄKTApurifierTM (GE 
Healthcare) and 1 ml fractions were collected, quantified (section 2.14), analysed 
by SDS-PAGE (section 2.15) and tested for thrombin and trypsin inhibition (section 
2.16). 
 
 
2.13. Purification of D1 
 
D1 was first purified by affinity chromatography in an immobilized-trypsin 
column. This column was prepared as described below. 
 
 
2.13.1. Preparation of the affinity column 
 
 An immobilized-trypsin affinity column was prepared by coupling bovine 
pancreatic trypsin (Sigma) to AminoLink Plus Coupling Resin (Thermo Scientific 
Pierce). Twenty millilitres of AminoLink Plus Coupling Resin were placed in a 
chromatography column (2.5 cm x 10 cm) and allowed to settle at room 
temperature. The bottom cap was opened and the storage solution was drained. 
The column was equilibrated with 100 ml of 0.1 M sodium phosphate pH 7.2, 0.15 
M NaCl (coupling buffer) and incubated with 300 mg of trypsin dissolved in 20 ml of 
coupling buffer (trypsin solution). Four hundred microlitres of 5 M 
cyanoborohydride solution were added and the mixture was incubated at 4 ºC 
overnight with gentle shaking by end-over-end rocking. After releasing the gas 
formed during the reaction by opening the top cap in a fume hood, the content was 
drained and collected. The flow-through obtained was used to determine the 
coupling efficiency by subtracting the trypsin amount present in the flow-through to 
the amount present in the initial trypsin solution. The column was washed with 80 
ml of coupling buffer followed by 100 ml of 1 M Tris-HCl pH 7.4 (quenching buffer). 
Two millilitres of quenching buffer and 40 μl of 5 M cyanoborohydride solution were 
added to the column in order to block the remaining active sites of the resin. The 
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matrix was gently mixed for 30 minutes by end-over-end rocking at room 
temperature. The gas formed during the reaction was first released in a fume hood 
and the content was drained. The column was washed with 150 ml of 1M NaCl 
followed by 200 ml of 20 mM Tris-HCl pH 8.0, 150 mM NaCl and was stored in 20 
mM Tris-HCl pH 8.0, 150 mM NaCl, 1 M benzamidine, 0.05% sodium azide at 4 
ºC.  
 Five hundred microlitres of resin were used to quantify the amount of active 
trypsin bound to the resin. The resin was added to a Poly-Prep® Column (Bio-rad) 
and equilibrated to room temperature. The storage solution was drained and the 
column washed with 20 ml of 50 mM Tris-HCl pH 8.0, 150 mM NaCl (binding 
buffer). Two millilitres of binding buffer with 8.4 mg of trypsin inhibitor from Glycine 
max (Sigma) were added to the column and the mixture was incubated for 1 hour 
at room temperature. The column was washed with 3 ml of binding buffer and the 
bound material was eluted with 2 ml of 0.2 M glycine-HCl pH 3.0. Five hundred 
microlitres fractions were collected and their pH adjusted to 7 by adding 25 µl of 1 
M Tris (pH not adjusted). The concentration of the collected fractions was 
determined by measuring the absorbance at 280 nm. The amount of trypsin 
inhibitor present in the collected fractions was used to calculate the binding 
capacity of the column.  
 
 
2.13.2. Purification of D1 
 
The supernatant obtained after D1 expression was filtered (0.45 µm pore) 
and applied to the immobilized-trypsin affinity column prepared as described in 
section 2.13.1 and previously equilibrated with at least 20 column volumes of 20 
mM Tris-HCl pH 8.0, 150 mM NaCl. The column was washed with at least 20 
column volumes of 20 mM Tris-HCl pH 8.0, 150 mM NaCl and bound proteins 
were eluted with 4 column volumes of 0.2 M glycine pH 3.0. The collected fractions 
were neutralized by adding 50 µl of 1 M Tris (pH not adjusted) per 1 ml of collected 
eluate. The most concentrated fractions were pooled and the buffer was 
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exchanged by 3 cycles of dialysis each against at least 100 sample volumes of 20 
mM Tris-HCl pH 8.0, 150 mM NaCl. The purified material was quantified and 
analysed by SDS-PAGE and activity assays as described in sections 2.14, 2.15 
and 2.16, respectively. 
 
 
2.14. Protein quantification 
  
Purified D1D2 and D1 were quantified by measuring the absorbance at 280 
nm on a NanoDrop ND-1000 Spectrophotometer (Thermo Scientific). This 
quantification is based on the Lambert-Beer law, which considers a linear 
relationship between absorbance and protein concentration. This law can be 
translated by the equation  CA , in which A corresponds to the absorbance 
represented in absorbance units (AU), C to the protein concentration in molarity 
(M) , ε to the extinction coefficient of the protein in units of M-1cm-1 and   to the 
path length of the sample in centimetres (cm). Before quantification, the molar 
extinction coefficient (ε) for each protein was estimated from the respective amino 
acid sequence using the ProtParam tool of the ExPaSy Proteomics Server 
(http://expasy.org/). 
 
 
2.15. SDS-PAGE 
 
 Samples from expression and purification of D1D2 and D1 were analysed 
by SDS polyacrylamide gel electrophoresis (SDS-PAGE). The SDS-polyacrylamide 
gels were composed by two layers. The stacking gel, with approximately 1 cm, was 
composed by 4% of acrylamide, 0.156 M Tris-HCl pH 6.8, 0.2% SDS, 0.1% APS 
and 0.1% TEMED. The separating gel was composed by 15 or 17% of acrylamide, 
0.5 M Tris-HCl pH 8.8, 0.2% SDS, 0.1% APS and 0.1% TEMED. All samples were 
prepared by adding 1/5 sample volume of loading buffer (10% w/v SDS, 20% v/v 
glycerol, 0.2 M Tris-HCl pH 6.8, 0.05% Bromophenol Blue, 1.8% 2-
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mercaptoethanol) followed by  incubation at 100 ºC for 10 minutes. SDS 
polyacrylamide gels were run at between 80 and 120 V in running buffer (24.8 mM 
Tris, 191.8 mM glycine and 0.1% SDS).  Afterwards the gels were washed 3 times 
in deionised water in order to remove SDS. Each wash was performed in a 
microwave on maximum power for 1 minute. Washed gels were stained with 
PageBlueTM (Fermentas) on a microwave for up to 30 seconds on maximum power 
followed by gentle agitation at room temperature for 30 minutes. After staining the 
gels were washed overnight with deionised water. 
 
 
2.16. Activity assay 
 
The inhibitory activity of D1D2 and D1 recombinant proteins was tested after 
the expression and purification steps by measuring the residual activity of trypsin 
and/or thrombin towards Bz-Phe-Val-Arg-pNA (Bachem) and Chromozym® TH 
(Tos-Gly-Pro-Arg-pNA) (Roche), respectively. Bovine pancreatic trypsin (5 µl, 160 
nM) or bovine thrombin (5 μl, 240 nM) was incubated with 1 to 80 µl of protein 
samples in assay buffer (100 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Triton X-
100) for 10 minutes at 37 ºC. After this first incubation, 5 µl of synthetic substrate 
(4 mM Bz-Phe-Val-Arg-pNA or 1.9 mM Chromozym® TH) was added and the 
reaction mixture (final volume of 100 μl) was incubated at 37 ºC for 10 minutes. 
The reaction was stopped by adding 50 µl of 50% (v/v) acetic acid after which the 
absorbance at 405 nm was measured using a Synergy 2 microplate reader 
(BioTek).  
 
 
2.17. Titration of trypsin 
 
A stock solution of 10 mg/ml trypsin was prepared in 1 mM HCl. In order to 
determine the amount of active trypsin present in the solution a titration was 
performed. Ten microlitres of trypsin solution (diluted 10 times) were incubated 
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with 10 µl of 10 mM 4-nitrophenyl 4-guanidinobenzoate hydrochloride (NPGB) in 
20 mM Tris-HCl pH 8.0, 150 mM NaCl to a final volume of 1 ml. The mixture was 
performed in a polystyrene cuvette and the reaction was followed by measuring the 
absorbance at 410 nm for 20 minutes (measurements every 5 seconds) at 37 ºC 
on a Shimadzu UV-2401 PC (Shimadzu Corporation). Measurement of a blank 
reaction containing 10 µl of 10 mM NPGB in 20 mM Tris-HCl pH 8.0, 150 mM NaCl 
(in the absence of proteolytic enzyme) was performed at the same time.  
The reaction of trypsin was calculated by subtracting the absorbance values 
corresponding to NPGB degradation (blank reaction) from the absorbance values 
obtained for the mixture of NPGB and trypsin. A linear regression analysis was 
applied to the values obtained (absorbance and time of reaction) and the 
absorbance for the time 0 determined. At this point the concentration of substrate 
cleaved was equal to the concentration of active trypsin. The active trypsin 
concentration was determined by using the equation  CA  (Lambert-Beer law), 
in which A corresponds to the absorbance represented in absorbance units (AU), 
C to the concentration of NPGB cleaved in molarity (M), ε to the extinction 
coefficient of NPGB (= 16.595 l mmol-1 cm-1) and   to the path length of the 
sample in centimetres (cm). 
  
 
2.18. Determination of the Michaelis-Menten constant of trypsin against 
Bz-Phe-Val-Arg-pNA 
 
Fifty microlitres of 6 nM active trypsin (in 50 mM Tris-HCl pH 8.0, 100 mM 
NaCl, 1 mg/ml BSA) were incubated with 50 µl of 1.56, 3.13, 6.25, 12.5, 25, 50, 
100, 200, 400 or 800 µM Bz-Phe-Val-Arg-pNA (in 50 mM Tris-HCl pH 8.0, 100 mM 
NaCl, 1 mg/ml BSA). The synthetic inhibitor cleavage reaction was followed at 37 
ºC for 1 hour using a Synergy 2 microplate reader (BioTek). The absorbance of the 
reaction mixture at 405 nm was measured every minute. Each condition was 
assayed in triplicate.  
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The concentration of reaction product (4-nitraniline) for each reading point 
was calculated by using the equation  CA , in which A corresponds to the 
absorbance represented in absorbance units (AU), C to the concentration of 
reaction product in molarity (M), ε to the extinction coefficient of the reaction 
product (= 10.4 l mmol-1 cm-1) and   to the path length of the sample in 
centimetres (cm). A linear regression analysis was performed on the linear region 
of the hydrolysis curve (defined by the product concentration and time of reaction) 
and only the curves with R square higher than 0.97 were considered for the 
determination of the reaction rate. The reaction rate for each substrate 
concentration was given by the slope of the respective equation bmXY   
(where Y corresponds to the concentration of reaction product, m to the slope of 
the straight line defined by the equation, X to the time and b to the product 
concentration at time 0) obtained by the linear regression analysis. These values 
were analysed using GraphPad Prism (Motulsky, 2008). Non-linear regression 
analysis using the Michaelis-Menten equation 
 
 
 
 
(v0 corresponds to initial reaction rate, Vmax to the maximum reaction rate, Km to 
the Michaelis-Menten constant and [S] to the substrate concentration) was 
performed on substrate concentrations and reaction rates.  
 
 
2.19. Determination of the inhibition constants of D1 and D1D2 towards 
bovine trypsin 
 
Fifty microlitres of 12 nM active trypsin (in 50 mM Tris-HCl pH 8.0, 100 mM 
NaCl, 1 mg/ml BSA) were incubated with 50 µl of 0.75, 1.5, 3, 6, 12, 24, 48, 96 and 
192 nM D1D2 or D1 (in 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mg/ml BSA) at 37 
ºC for 10 minutes. After adding 100 µl of 400 µM Bz-Phe-Val-Arg-pNA (in 50 mM 
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Tris-HCl pH 8.0, 100 mM NaCl, 1 mg/ml BSA), the mixture was incubated at 37 ºC 
for 1 hour. The absorbance of the mixture at 405 nm was measured every 15 
seconds. Each condition was assayed in triplicate. 
The concentration of reaction product (4-nitraniline) for each reading point 
was calculated using the equation  CA , in which A corresponds to the 
absorbance represented in absorbance units (AU), C to the concentration of 
reaction product in molarity (M), ε to the extinction coefficient of the reaction 
product (= 10.4 l mmol-1 cm-1) and   to the path length of the sample in centimetre 
(cm). A linear regression analysis was performed on the linear region of each 
hydrolysis curve (defined by the product concentration and time of reaction) and 
only the curves with R square higher than 0.97 were considered for the 
determination of the reaction rate. The reaction rate for each inhibitor concentration 
was given by the slope of the respective equation bmXY   (where Y 
corresponds to the product concentration, m to the slope of the straight line defined 
by the equation, X to the time and b to the product concentration at time 0). These 
values were analysed using GraphPad Prism (Motulsky, 2008). Non-linear 
regression analysis using the Morrison equation  
 
 
 
 
 
(v is the measured reaction rate, v0 is the reaction rate in the absence of inhibitor, 
[E]0 is the total enzyme concentration, [I] is the added inhibitor concentration and 
KI-app is the apparent equilibrium inhibitor constant) was performed on inhibitor 
concentrations and reaction rates.  
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2.20. Crystallization of D1 
 
Initial crystallization conditions were screened at 293 K using the sitting-drop 
method with commercial crystallization screens: Crystal Screen, Crystal Screen 2 
and PEG-Ion from Hampton Research, and Morpheus from Molecular Dimensions. 
The drops contained equal volumes (2 μl) of protein solution (≈10 mg/ml in 20 mM 
Tris-HCl pH 8.0, 150 mM NaCl) and precipitant, equilibrated against a 300 μl 
reservoir. D1 crystals were obtained using 1.0 M lithium sulfate monohydrate and 
2% (w/v) PEG 8000 as precipitant. Crystals were sequentially transferred to 
solutions of precipitant containing 5, 10, 15, 20 and 25% of glycerol as 
cryoprotectant and then cryo-cooled in liquid nitrogen. 
 
 
2.21. Data collection and processing 
 
Diffraction data was collected on an Onyx CCD Detector in an Oxford 
Diffraction Gemini PX Ultra diffractometer using CuKα radiation. A single cryo-
cooled crystal of D1 was used and data were measured in 1º oscillation steps with 
an 80 mm sample-to-detector distance and 6 minutes exposure per frame. Two 
hundred and ninety one frames were collected. 
Diffraction data were integrated with CrysAlisPro Software (Oxford 
Diffraction) and scaled using SCALA (Evans, 2006) from the CCP4 program suite 
(Collaborative Computational Project No. 4, 1994).  
 
 
2.22. D1 structure solution 
 
 The structure of D1 was solved by molecular replacement with PHASER 
(McCoy et al., 2007) from the CCP4 program suite (Collaborative Computational 
Project No. 4, 1994) using the coordinates for the N-terminal domain of boophilin 
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(residues Gln16 to Ala58) from PDB entry 2ODY (Macedo-Ribeiro et al., 2008) as 
search model. The model was subjected to alternating cycles of manual building 
with Coot (Emsley et al., 2010) and crystallographic refinement with PHENIX 
(Adams et al., 2010). 
 
 
 
2.23. Trypsin-D1 complex preparation 
 
The macromolecular complex was prepared by mixing bovine pancreatic 
trypsin (Sigma) with a 10% molar excess of purified D1. The mixture was 
incubated on ice for 1 hour, and the trypsin-D1 complex was separated from the 
excess of inhibitor by size exclusion chromatography on a Superdex 75 column 
(Amersham Pharmacia), using 20 mM Tris-HCl pH 8.0, 150 Mm NaCl as the 
mobile phase. The absorbance at 280 nm was monitored on an ÄKTApurifierTM 
(GE Healthcare). Fractions of 1 ml were collected and analyzed by SDS-PAGE 
(see section 2.15) and those containing the trypsin·D1 complex were pooled and 
concentrated on a 3 kDa cut-off centrifugal concentrator (Vivaspin 2, GE 
Healthcare).  
 
 
2.24. Crystallization of trypsin-D1 complex 
 
Initial crystallization conditions were screened at 293 K using sitting drops 
with commercial crystallization screens: Crystal Screen, Crystal Screen 2, PEG-Ion 
and Index from Hampton Research, and Proplex, Morpheus and JCSG-plus from 
Molecular Dimensions. The drops contained equal volumes (2 μl) of complex 
solution (≈10 mg/ml in 20 mM Tris-HCl pH 8.0, 150 mM NaCl) and precipitant 
solution, equilibrated against 300 μl reservoir. Crystals were obtained using 0.10 M 
carboxylic acids (0.033 M sodium formate, 0.033 M sodium citrate, 0.033 M 
sodium oxamate), 0.1 M buffer pH 6.5 (0.025 M imidazole, 0.025 M sodium 
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cacodylate, 0.025 M MES, 0.025 M BIS-TRIS), 12.5% (v/v) MPD, 12.5% (w/v) PEG 
1000, 12.5% (w/v) PEG 3350 as precipitant solution. Some crystals were cryo-
cooled in liquid nitrogen.  
In order to find a condition able to produce better crystals, new solutions 
were prepared by varying the pH (pH 6.0, 6.5 and 7.0) and/or the percentage of 
MPD, PEG 1000 and PEG 3350 present in the initial condition (see Table 1 for 
details). The complex solution was incubated with these new solutions at 293 K in 
sitting-drop plates. 
 
 
Table 1 – Scheme of new precipitant solutions composition. Twenty four precipitant solutions (PS) 
were prepared by varying the buffer pH and the percentage of MPD, PEG 1000 and PEG 3350 
used in the initial precipitant solution.  
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3. Results and discussion 
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3.1. DNA sequence analysis of pPICZαB-D1 and pPICZαB-D1D2 
 
The expression vectors pPICZαB-D1 and pPICZαB-D1D2 required for the 
expression of D1 or D1D2, respectively, in yeast were initially sequenced (MWG 
Eurofins) in order to verify that the nucleotide sequence was correct, using primer 
5’AOX1. Figure 9 represents the amino acid sequence of the D1 and D1D2 
recombinant proteins encoded by these vectors. Both proteins are fused to an N-
terminal secretion signal termed α-factor. This peptide corresponds to the 
sequence of the S. cerevisiae α-factor prepro peptide and allows the secretion of 
the D1 and D1D2 proteins into the expression medium. 
After the translation of the recombinant protein α-factor-D1 or α-factor-D1 
D2 in P. Pastoris the N-terminal signal peptide is processed. The processing 
involves the removal of the pre signal (represented in dark grey in Figure 9, A) by 
a signal peptidase in the endoplasmic reticulum followed by cleavage by Kex2 
endopeptidase after Lys-Arg (Kex2 endopeptidase processing site) present at the 
end of the signal peptide sequence (Cereghino and Cregg, 2000). 
There are two described variants of boophilin: isoform H2 and isoform G2 
with GenBank access numbers CAC82583.1 and CAC82582.1, respectively. The 
D1 and D1D2 recombinant proteins encoded by the plasmids pPICZαB-D1 and 
pPICZαB-D1D2, respectively were aligned with these two isoforms (Figure 9, B). 
The D1 sequence corresponds to the first BPTI-Kunitz domain of boophilin G2 
isoform. In its sequence a mutation was found in residue position 27, where the 
glutamic acid was substituted by a glutamine (Figure 9, B). The D1D2 sequence 
encodes for the full-length boophilin G2 isoform. Its sequence had two mutations 
when compared to the sequence of boophilin G2 isoform. The first mutation was 
similar to the one found in D1 sequence. The second mutation was localized in 
residue position 92, where the alanine was substituted by a threonine (Figure 9, 
B).  Both mutations are conservative and consequently are not predicted to 
severely affect the inhibitor-proteinase interaction. The crystallographic structure of 
D1D2 in complex with thrombin (PBD: 2ODY) also supports this idea since it 
shows that these mutations are localized in regions that are not involved in 
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thrombin-D1D2 interaction (Figure 10). Because boophilin used two different 
inhibition mechanisms against trypsin and thrombin, the effect of these mutations 
on trypsin-boophilin interaction should be clarified.   
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Figure 9 –   Amino acid sequence alignment of recombinant D1 and D1D2 proteins encoded by 
pPICZαB-D1 and pPICZαB-D1D2, respectively, with the α-factor (A) and with boophilin isoforms H1 
and G2 (B). A – The sequence represented in grey corresponds to the α-factor signal sequence. 
The pre signal sequence of the α-factor is shadowed in dark grey. α-factor is separated from D1 or 
   
 
                     1        10        20        30        40        50 
                     |        |         |         |         |         |         
        α-factor     MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSN 
      pPICZαB-D1     MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSN 
    pPICZαB-D1D2     MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLPFSN 
 
                      
                       60        70        80        90        100       110 
                       |         |         |         |         |         |                                 
        α-factor     STNNGLLFINTTIASIAAKEEGVSLEKR----------------------------- 
      pPICZαB-D1     STNNGLLFINTTIASIAAKEEGVSLEKRQRNGFCRLPADQGICKALIPRFYFNTETG 
    pPICZαB-D1D2     STNNGLLFINTTIASIAAKEEGVSLEKRQRNGFCRLPADQGICKALIPRFYFNTETG 
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                          |         |         |         |         |         |          
        α-factor     --------------------------------------------------------- 
      pPICZαB-D1     KCTMFSYGGCGGNENNFETIEDCQKACGA---------------------------- 
    pPICZαB-D1D2     KCTMFSYGGCGGNENNFETIEECQKACGAPERVSDFEGADFKTGCEPTADSGSCAGQ 
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        α-factor     ----------------------------------------- 
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    pPICZαB-D1D2     ---------------QRNGFCRLPADQGICKALIPRFYFNTETGKCTMFSYGGCGGN 
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D1D2 proteins after cleavage by Kex2 endopeptidase. The Kex2 recognition site is represented 
highlighted in red and the cleavage site is indicated by an arrow. B – The sequences for mature D1 
and D1D2 are shown in grey. The amino acid differences between the two isoforms of boophilin are 
shown in green. Two mutations (red) were found in the D1D2 sequence. One mutation is also 
present in the D1 sequence. 
 
 
 
Figure 10 – Crystallographic structure of boophilin in complex with thrombin showing the 
localization of mutations. The two images show the same complex in different positions. The right 
image was rotated 90º compared to the left image. Thrombin is represented by its electrostatic 
surface potential, while boophilin is shown as an orange ribbon. The localization of the mutations is 
in green. 
 
 
3.2. Genomic DNA analysis 
 
The expression vectors pPICZαB-D1 and pPICZαB-D1D2 were integrated 
into the P. pastoris genome in order to maximize the stability of transformants. To 
confirm that no mutations had occurred during the transformation and integration 
processes, the gDNA of the transformed cells was extracted for subsequent 
sequence analysis of the integrated sequences.  
       x 
    90º 
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After gDNA extraction, the quality of DNA obtained was assessed by 
spectrophotometric analysis. (see Table 2). The ratio between the absorbance at 
260 nm and 280 nm obtained for each sample was between 1.80 and 2.00, 
revealing that the samples were not contaminated with proteins. On the other 
hand, the ratio between the absorbance at 260 nm and 230 nm was smaller than 
the common values of 2.0-2.2. This indicated that all samples were contaminated 
with phenol. The concentration of this contaminant was higher in the DNA purified 
from cultures of pPICZαB-D1D2 transformants (D1D2 (A) and D1D2 (B)). 
The quality of gDNA extracted was also assessed by electrophoretic 
analysis (Figure 11). This analysis revealed that the concentration of the gDNA 
extracted form each culture of pPICZαB-D1D2 transformants was significantly 
higher compared to the gDNA obtained from each culture of pPICZαB-D1 
transformants (D1 (A) and D1 (B)). This concentration difference was not in 
agreement with the concentration values determined by spectrophotometry. 
Probably due to the high DNA concentration, it was also possible to observe some 
DNA degradation in D1D2 (A) and D1D2 (B) samples when examined by 
electrophoresis (Figure 11). The gDNA extracted from each culture of pPICZαB-
D1 transformants showed a high degree of integrity (Figure 11), however the 
amount of DNA applied to the gel was significantly lower compared to the D1D2 
(A) and D1D2 (B) samples. 
 
 
Table 2 – Spectrophotometric analysis of genomic DNA.  
 
 
 
Sample 
Concentration 
(ng/μl) 
nm280
nm260
OD
OD
 
nm230
nm260
OD
OD
 
D1 (A) 567.6 1.91 1.75 
D1 (B) 907.0 1.91 1.74 
D1D2 (A) 823.0 1.88 1.49 
D1D2 (B) 1071.0 1.90 1.47 
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Figure 11 – Electrophoretic analysis of the isolated genomic DNA from pPICZαB-D1D2 (D1D2 A 
and B) and pPICZαB-D1 (D1 A and B) transformants. Five (5) and ten (10) microlitres of each 
sample were separated in a 2% agarose gel. 
 
 
3.3. Amplification of α-factor-D1 and α-factor-D1D2 cDNA 
 
The gDNA extracted from pPICZαB-D1D2 (A and B) and pPICZαB-D1 (A 
and B) transformants were used as templates for the amplification of α-factor-
D1D2 and α-factor-D1 cDNA by PCR using the primers 3’AOX1 (5’-
GCAAATGGCATTCTGACATCC-3’) and 5’AOX1 (5’-
GACTGGTTCCAATTGACAAGC-3’). For the reaction conditions tested, the 
amount of PCR product obtained when D1D2 DNA was used as a template was 
lower than when the template was D1 DNA (Figure 12). The low amount of PCR 
product obtained when D1D2 DNA was used as a template was probably due to 
Pfu DNA polymerase inhibition. The inhibition of the enzyme was probably caused 
by the presence of significant amounts of phenol in the D1D2 DNA samples and/or 
by high DNA concentration in the PCR mixture due to an incorrect quantification. 
             D1D2 (A)       D1D2 (B)     D1 (A)      D1 (B) 
              5    10           5    10           5   10          10 
1000 bp 
3000 bp 
6000 bp 
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A small band of contaminant with about 700 bp was observed in both D1D2 
(A) and negative control PCR reactions (Figure 12, Lane B and E). This 
contaminant had a size similar to that of the α-factor-D1 PCR product 
(approximately 700 bp). As a possible α-factor-D1 cDNA contaminant, it was 
ignored and the D1 (A) PCR product (700 bp) was purified and analysed by DNA 
sequencing.  
In order to increase the amount of α-factor-D1D2 cDNA a new PCR was 
performed using the D1D2 (B) PCR product (Figure 12, Lane A) as template. The 
amount of cDNA obtained was significantly higher; however the same band of 
contaminant was observed (Figure 13). The cDNA of α-factor-D1D2 was isolated 
from the gel and the DNA purified and analysed by DNA sequencing.   
 
 
 
Figure 12 – Electrophoretic analysis of the products obtained by PCR reaction performed with 
genomic DNAs. Ten microlitres of each sample were resolved in a 2% agarose gel. Templates in 
each lane: A – D1D2 (B); B – D1D2 (A); C – D1 (B); D – D1 (A); E – Negative control. 
 
 
 
 
    A      B      C      D      E 
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Figure 13 – PCR product obtained after amplification of α-factor-D1D2 (B) cDNA. Ten microlitres of 
PCR reaction mixture were separated in a 2% agarose gel.  A band of contaminant was observed 
in the PCR reaction mixture. A – Negative control. B – PCR reaction mixture. 
 
 
3.4. DNA sequence analysis of α-factor-D1 and α-factor-D1D2 cDNA 
integrated into Pichia pastoris genome 
 
The purified α-factor-D1 and α-factor-D1D2 cDNA amplified by PCR were 
analysed by DNA sequencing. The DNA sequences obtained were translated to 
amino acid sequence and aligned with the α-factor-D1 or α-factor-D1D2 amino 
acid sequences encoded by the plasmids. No differences were observed between 
the sequences encoded by the cDNA of the plasmids or the cDNA integrated into 
the yeast cells genome (Figure 14). Thus, no mutations that could lead to an amino 
acid exchange had occurred during transformation and integration of the plasmids 
into the yeast cells. 
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Figure 14 – Amino acid sequence alignment between the sequence encoded by the plasmids 
pPICZαB-D1 and pPICZαB-D1D2 or by the α-factor-D1 or α-factor-D1D2 cDNAs integrated into the 
genome. The sequence of α-factor is represented in dark grey and the sequences of D1 and D1D2 
are represented in light grey. No differences were observed between the sequences encoded by 
the plasmids or by the genome. 
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                        |        |         |         |         |         | 
       D1plasmid        MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDV 
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                                 |         |         |         |         | 
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3.5. Expression of D1D2 
 
After obtaining the desired biomass, the expression of recombinant D1D2 
was induced by substituting the growth medium (containing glycerol) for the 
induction medium (containing methanol). The induction was performed for 5 days, 
by adding methanol every 24 hours.  
The expression and secretion of D1D2 was confirmed by SDS-PAGE and 
by activity assays at the end of the fifth day of induction. The supernatant obtained 
after D1D2 expression originated two bands in a SDS polyacrylamide gel (Figure 
15, Lane 3). The higher molecular band is the more intense and corresponds to 
D1D2. This protein revealed an apparent molecular weight of about 18 kDa, which 
is higher than the value determined by mass spectrometry (13.9 kDa). This 
anomalous migration in SDS-polyacrylamide gels appear to the related to the 
acidic character of D1D2 (theorical pI: 4.41), which could interfere with SDS 
binding. The lower molecular weight band showed an apparent molecular weight 
of about 14 kDa and it is a putative degradation product of the full-length protein.  
It was also possible to observe the presence of a smear in the D1D2 supernatant 
lane (Figure 15, Lane 3), which corresponds to the medium components and to 
the other proteins secreted by P. pastoris. 
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Figure 15 – Expression and secretion of D1D2 protein in P. pastoris. Ten microlitres of each 
sample were separated in a 15% polyacrylamide gel. The gel was stained with PageBlue
TM
. Lane 1 
– Culture before induction. Lane 2 – Culture after induction. Lane 3 – Culture medium collected 
after the fifth day of induction. The band with higher molecular weight corresponds to D1D2 and the 
one with lower molecular weight (*) to degradation products. Lane 4 – Whole cell extract. 
 
 
 
The presence of D1D2 in the culture medium was also confirmed by testing 
its ability to inhibit trypsin and thrombin in an in vitro activity assay. Both 
proteinases were inhibited by the supernatant obtained after D1D2 expression 
(Figure 16). The inhibition was dose-dependent.  
 
 
 
 
 
 
 
 
 
 
 
 
1 
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Figure 16 – The supernatant obtained after D1D2 expression showed anti-trypsin and anti-
thrombin activity. Different volumes of supernatant (diluted 300x) were incubated with trypsin (A) 
and thrombin (B) and the residual activity was measured at 405 nm after addition of a synthetic 
substrate. 
 
 
3.6. Purification of D1D2 
 
 The secretion of D1D2 to the culture medium helped the purification of the 
recombinant protein, since the yeast secretes only low levels of its own proteins. 
D1D2 was purified in two chromatographic steps: affinity chromatography followed 
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by an ion-exchange chromatography. For the first step of purification an 
immobilized-trypsin column was prepared. The efficiency of trypsin coupling was 
confirmed and the binding capacity of the column was quantified.   
 
 
3.6.1. Preparation of the affinity column 
 
The amount of trypsin coupled to the CNBr-activated Sepharose 4B was 
determined by subtracting the trypsin amount present in the flow-through obtained 
after incubating the medium with a trypsin solution of known concentration from 
the trypsin amount present in this last one. The concentration of trypsin solution 
was determined by measuring the absorbance at 280 nm and the value obtained 
was 62,322 mg/ml. In the 12 ml of trypsin solution there were 748 mg of trypsin. 
After coupling, the flow-through obtained was dialyzed and then quantified by 
measuring the absorbance at 280 nm. From the 748 mg of trypsin used only 16.5 
mg was present in flow-through. In conclusion, ninety eight percent (731.5 mg) of 
the initial trypsin was bound to the medium.  
Once prepared, the binding capacity of the column was quantified. Twelve 
milligrams of Glycine max trypsin-chymotrypsin inhibitor (7.5 kDa) was applied to a 
1 ml column. The eluted fractions were quantified by measuring the absorbance at 
280 nm. Only 1.691 mg of trypsin inhibitor was eluted from the column. Since the 
interaction of trypsin-trypsin inhibitor is of 1:1 molar ratio then the number of moles 
of active trypsin bound to the column is equal to the number of moles of eluted 
trypsin inhibitor. Thus, 2.25x10-7 mol of trypsin was active in the 1 ml column 
(binding capacity of the column). This means that only 12.8% (93.7 mg) of coupled 
trypsin (731.5 mg) could be inhibited. 
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3.6.2. Purification of D1D2 
 
Recombinant D1D2 was first purified by affinity chromatography on an 
immobilized-trypsin affinity column. This first purification step allowed to separate 
the D1D2 protein and the putative degradation product that was able to interact 
with trypsin from other medium components. The fractions collected during elution 
with 1 M benzamidine showed two bands after separation on a SDS 
polyacrylamide gel (Figure 17, Lane 3-6). The higher molecular weight band with 
about 18 kDa is the more intense and corresponds to D1D2. If the lower molecular 
weight band (approximately 13 kDa) corresponds to the degradation product it 
probably contains the first domain of boophilin; otherwise it would not interact with 
trypsin. After elution the samples were pooled together and the benzamidine 
removed by dialysis. In spite of the high concentration of benzamidine used a 
significant amount of D1D2 remained attached to the column after elution (Figure 
17, Lane 2). The elution by competition with 1 M benzamidine was not effective. 
Higher concentration of benzamidine would increase the cost associated to the 
elution, and would require extensive dialysis in order to eliminate the benzamidine 
from the purified fractions. Thus, the elution with benzamidine should be replaced 
by a more efficient and affordable elution method. 
 
 
 
 
Figure 17 – Immobilized-trypsin affinity chromatography as first step on D1D2 purification. Ten 
microlitres of each sample were separated in a 15% polyacrylamide gel. The gel was stained with 
PageBlue
TM
. Lane 1 – Column material before injection of supernatant. The higher molecular 
weight corresponds to trypsin and the lower molecular weight bands to trypsin degradation 
25 kDa 
20 kDa 
15 kDa 
10 kDa 
  1  2  3   5    4   6 
D1D2 
Trypsin 
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products. Lane 2 – Column material after injection of supernatant and elution of bound proteins. 
D1D2 band is present in this lane (indicated by a rectangle). Lane 3 to 6 – Fractions collected 
during elution of bound proteins.  
 
  
If the lower molecular band observed on the purified fraction after 
separation by SDS-PAGE corresponds to a degradation product of D1D2 it 
certainly contains D1. On the other hand, the difference on the molecular weight 
observed between the two bands suggests that the D2 is absent in the 
degradation product.  
The theorical isoelectric point of D1 is 6.29, which should be similar to the 
isoelectric point of the degradation product found after the first step of D1D2 
purification. The D1D2 has a lower theorical isoelectric point compared to D1 
(4.41). Thus, the difference in pI could be used to separate these two proteins. The 
charge difference observed between D1D2 and D1 was significantly high to 
promote their separation by an ion-exchange chromatography in a positively 
charged column (Mono Q) at pH 8.0.  
The injection of the sample and elution of bound protein were monitored at 
214 nm and 280 nm on an ÄKTApurifierTM (GE Healthcare). The most sensitive 
setting is at 214 nm, which detects absorbance of the peptide bond. The 
absorbance at 280 nm is due to the presence of tyrosine and tryptophan (aromatic 
residues). The tyrosine and tryptophan content of various proteins varies with 
narrow limits and thus, the absorbance at this wavelength as been used as a rapid 
and fairly sensitive measure of protein concentration. In the chromatogram 
obtained during elution of bound proteins with a linear gradient from 0 to 1.0 M 
NaCl two peaks were observed. The first peak was very small and almost 
undetectable at 280 nm (Figure 18, A, peak *). This peak eluted at a concentration 
of about 0-0.2 M of NaCl. The second peak was bigger and presented a small 
shoulder (Figure 18, A, peak **). This higher peak was obtained at approximately 
0.4 M of NaCl. The ionic strength needed to produce this peak was higher 
compared to the first one, and thus it must correspond to D1D2 because this 
protein is more negatively charged than D1 at pH 8.0.  
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The flow-through collected during sample injection and the fractions 
collected during elution of bound proteins were resolved in a SDS-polyacrylamide 
gel. The concentration of the first peak fractions was too low and no proteins were 
detected by SDS-PAGE. The fractions of the second peak showed a single band 
with a molecular weight of about 18 kDa similar to the D1D2 protein (Figure 18, B). 
Despite the presence of a shoulder in the second peak, no additional bands were 
detected. Due to the fact that the sample injected into the column was fairly diluted 
(in order to decrease the concentration of salt) the protein concentration of the flow 
through was also low. Therefore, in order to analyse the content of the flow-
through by SDS-PAGE the fraction was first lyophilized and resuspended in the 
smaller volume of water possible. On a SDS polyacrylamide gel, the concentrated 
flow-through showed a single band with a molecular weight similar (approximately 
13 kDa) to the degradation products found in the affinity chromatography fractions 
(Figure 18, C). 
The activity assay with trypsin showed anti-trypsin activity for all fractions of 
both peaks (Figure 19, A) and for flow-through (Figure 19, B). This assay, much 
more sensitive than SDS-PAGE, showed the complete separation of the two 
proteins obtained after affinity chromatography (Figure 19). A second activity assay 
with thrombin was also performed, confirming the presence of D1D2 only in the 
fractions corresponding to the second peak. This assay was not quantified and the 
inhibitory activity was only confirmed by the absence of yellow colour after 
incubation with substrate, in contrast with the positive control. The yellow colour 
results from substrate cleavage by the enzyme, being absence in the negative 
control, in which no enzyme or inhibitor was added.  
 
 
 
 
 
 
 
 
Characterization of trypsin inhibition by boophilin 
 
 
78 
 
 
Figure 18 – Purification of D1D2 by ion exchange chromatography. A – Chromatogram obtained 
during elution of bound proteins. First peak (*) corresponds to the degradation products containing 
the D1 and the second peak (**) to D1D2. B – Ten microlitres of start material (SM) and of each 
collected fraction (orange in the chromatogram) were separated in 15% polyacrylamide gels. The 
gel was stained with PageBlue
TM
. Only fractions B3 to B6 had detectable amounts of protein. C – 
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Ten microlitres of flow through material (FT), concentrated by liofilization, was resolved in a 15% 
polyacrylamide gel stained with PageBlue
TM
.  
 
 
 
Figure 19 – Anti-trypsin activity was observed for fractions of both peaks and flow-through. Five 
microlitres of each collected fraction (A) and 50 µl of flow-through (B) were incubated with trypsin 
and its residual activity was determined by measuring the absorbance at 405 nm after adding the 
substrate.  
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3.7. Expression of D1 
 
The expression of D1 was confirmed at the end of the fifth day of induction 
by SDS-PAGE and activity assays. The supernatant obtained after D1 expression 
showed a single band on the SDS polyacrylamide gel with an apparent molecular 
weigh of about 10 kDa (Figure 20, Lane 3). This band corresponds to D1. It was 
also possible to observe the presence of a light smear in D1 supernatant lane 
(Figure 20, Lane 3), which corresponds to the medium components and to the 
other proteins secreted by P. pastoris.  
 
 
 
Figure 20 – Expression and secretion of D1. Ten microlitres of each sample were resolved in a 
15% polyacrylamide gel stained with PageBlue
TM
. Lane 1 – Culture before induction Lane 2 – 
Culture after induction; Lane 3 – Supernatant. Only the D1 band was detected. Lane 4 – Whole cell 
extract. 
 
 
 The presence of D1 in the supernatant was also confirmed by performing 
activity assays with trypsin and thrombin. Only trypsin was inhibited by the D1 
supernatant (Figure 21). D1 was unable to inhibit thrombin, suggesting that the 
second domain of boophilin is required for the interaction of the inhibitor with the 
thrombin proteinase. 
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Figure 21 – Supernatant obtained after D1 expression showing anti-trypsin activity. No inhibition 
was observed for thrombin. Different volumes of supernatant (diluted 50x) were incubated with 
trypsin and thrombin and their residual activity was measured at 405 nm after adding the respective 
substrate.  
 
 
3.8. Purification of D1 
 
 The secretion of D1 by P. pastoris was a great first step of purification, 
because P. pastoris only secretes low levels of its own proteins. D1 was purified by 
a single affinity chromatography in an immobilized-trypsin column. The column 
used to purify D1 was prepared and its binding capacity determined.   
 
 
3.8.1. Preparation of the affinity column 
 
The trypsin amount coupled to the AminoLink Plus Coupling Resin (Thermo 
Scientific Pierce) was determined by subtracting the trypsin amount present in 
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concentration from the trypsin amount present in the initial trypsin solution. The 
concentration of trypsin solution and flow-through was determined by measuring 
the absorbance at 280 nm. The total amount of trypsin present in trypsin solution 
was 246.5 mg and from those, only 1.41 mg were found in flow-through. In 
conclusion, 99.43% (245.09 mg) of the initial trypsin was coupled to the resin. 
  Once prepared, the binding capacity of the column was quantified by 
applying trypsin inhibitor from Glycine max (20.1 kDa) to a 500 µl column. The 
concentration of eluted material was determined by measuring the absorbance at 
280 nm. The total mass of eluted inhibitor was 0.523 mg. Since the interaction of 
trypsin-trypsin inhibitor is of 1:1 molar ration then the number of moles of active 
trypsin bound to the column is equal to the number of moles of eluted trypsin 
inhibitor. Thus, 2.66x10-8 mol of active trypsin was present in the 500 µl column. 
The binding capacity of the column prepared was 5.32x10-8 mol per millilitre of 
column. In conclusion, from the 245.09 mg of coupled trypsin, 10.3% (25.3 mg) 
was active.  
 
 
3.8.2. Purification of D1 
 
The purification of D1 was achieved by a single chromatography on an 
immobilized-trypsin affinity column. The absorbance at 280 nm of eluted fractions 
was determined in order to identify the fractions containing protein (Figure 22, A). 
The fractions containing a detectable amount of protein at 280 nm were analysed 
by SDS-PAGE and only a band with a molecular weight similar to that of D1 was 
detected. An activity assay with trypsin was also performed (Figure 23) and all 
fractions tested showed significant inhibitory activity against trypsin. The fractions 
4-11 were polled together since they contained significant amounts of D1.  
In order to avoid protein loss, the column flow-through was collected in 
fractions (FT1, FT2, and FT3) and analysed by SDS-PAGE (Figure 22, B) and by 
activity assays (Figure 23). Those flow-through fractions containing inhibitory 
activity against trypsin were reinjected into the column and bound proteins eluted.  
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Figure 22 – Purification of D1 by affinity chromatography. A –The absorbance at 280 nm of the 
purified fractions was determined and only those fractions corresponding to the peak of elution (3-
12) are shown in the graphic. No significant absorbance values were observed for the other 
fractions. B – Ten microlitres of supernatant (S) and of each flow through fraction (FT1, FT2, FT3) 
and 5 microlitres of each purified fraction (3-11) were separated in a 15% polyacrylamide gel 
stained with PageBlue
TM
.  
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Figure 23 – Anti-trypsin activity was observed for all purified fractions of D1. One microlitre of each 
purified fraction and 5 µl of each flow through fraction were incubated with trypsin and its residual 
activity was measured at 405 nm after adding the substrate. Anti-trypsin activity was observed for 
all purified fractions and for all flow-through fractions (FT1, FT2, and FT3). 
  
 
3.9. Trypsin titration 
 
In order to study the inhibition of trypsin by D1 or by D1D2 it was necessary 
to first titrate trypsin. Trypsin is a very active enzyme that is prone to autolysis. 
Trypsin self-cleavage leads to the inactivation of its enzymatic activity. Therefore 
the amount of active trypsin in stock solutions subsequently used in the enzymatic 
assays was calculated. This was done by incubating trypsin with NPGB and by 
following the reaction at 410 nm for 20 minutes (measurements every 5 seconds) 
at 37ºC (Figure 24, A, dark blue line). The cleavage of NPGB produces a yellow 
colour detectable at the wavelength used. 
 NPGB is a suicide trypsin substrate meaning that after being cleaved by the 
protease the cleavage product is not released. Since the cleavage product 
remains attached to trypsin the cleavage of additional substrate molecules is 
consequently avoided. This feature allows the quantification of active trypsin in a 
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certain solution by determination of the amount of substrate (from a known 
substrate concentration solution) that is cleaved by the enzyme. However, NPGB 
by itself is slightly unstable in aqueous solutions and starts to degrade (Figure 24, 
A, light blue line). For this reason, the degradation of NPGB in the absence of 
protease was also followed in the same experimental conditions. This was used as 
a blank control. The absorbance values corresponding to the cleavage of NPGB 
by trypsin were later calculated by subtracting the absorbance values of the NPGB 
degradation from the absorbance values of the mixture (Figure 24, B). Three 
independent experiments were performed.   
A linear regression analysis was performed on absorbance values 
(dependent variable) and time of reaction (independent variable) obtained for each 
experiment. The slope (y/x, where y is the difference between two absorbance 
values and x is the interval of time in which y is observed) given by the equation 
bmXY   (where Y corresponds to the absorbance represented in AU, m to the 
reaction rate in AU sec-1, X to the time in seconds, and b to the absorbance in AU 
at time 0) obtained after linear regression analysis is near zero revealing the 
inhibition of trypsin by NPGB (see Table 3). The number of active trypsin 
molecules is given by the number of substrate molecules cleaved at time 0. The 
absorbance at time 0 was determined and the concentration of active trypsin 
calculated by using the equation  CA , in which A corresponds to the 
absorbance represented in (AU), C to the concentration of cleaved NPGB in 
molarity (M), ε to the extinction coefficient of NPGB (= 16.595 l mmol-1 cm-1) and   
to the path length of the sample in centimetre. The concentration of active trypsin 
was given by the mean of the concentration values determined in each experiment 
(Table 3). 
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Figure 24 – Titration of trypsin with NPGB. A – A mixture containing trypsin and NPGB was 
incubated at 37 ºC and the reaction was followed by measuring the absorbance at 410 nm (dark 
blue). In parallel, the degradation of NPGB in the assay buffer was also followed (light blue). B – 
The cleavage of NPGB by trypsin was obtained by subtracting the absorbance values produced by 
NPGB degradation from the absorbance values of the mixture containing trypsin and NPGB. 
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Table 3 – Active trypsin concentration. Three independent experiments were performed. The active 
trypsin concentration was given by the mean of the concentration values obtained for each 
experiment. 
 
Number of experiments Linear regression 
Active trypsin concentration 
(mg/ml) 
1 
Y = 9.0x10
-6
X + 2.73x10
-2
 
R
2 
= 0.990 
7.83 
2 
Y = 8.0x10
-6
X + 2.53x10
-2 
R
2 
= 0.988 
7.26 
3 
Y = 5.0x10
-5
X + 2.53x10
-2
 
R
2 
= 0.998 
7.26 
  7.45 ± 0.33 
 
 
  
3.10. Determination of the maximum reaction rate and Michaelis-Menten 
constant of trypsin against Bz-Phe-Val-Arg-pNA 
 
In order to determine the inhibition constants of D1 and D1D2 against 
trypsin it was necessary to calculate not only the concentration of active trypsin in 
the stock solutions used (explained above) but also to determine the Michaelis-
Menten constant of trypsin against the synthetic substrate Bz-Phe-Val-Arg-pNA 
(explained below). 
The maximum reaction rate (Vmax) and the Michaelis-Menten constant (Km) 
are two parameters which define the kinetic behaviour of an enzyme. The Vmax is a 
rate of reaction and it is the limiting value of the initial rate when all the active sites 
are occupied with substrate. This parameter is related to the amount of enzyme or 
substrate used in the reaction. By contrast, Km is independent on the enzyme or 
substrate concentration and it is always the substrate concentration required to 
achieve half of Vmax. This parameter is inherent to the enzyme and is a measure of 
its activity. Km is related to the dissociation constant and gives an indication of the 
enzyme affinity to a specific substrate: high Km values indicate high affinity.  
In order to determine these two parameters, trypsin was incubated with 
different concentrations of the synthetic substrate Bz-Phe-Val-Arg-pNA and the 
reaction was followed at 405 nm for 1 hour (measurements every minute) at 37 ºC. 
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The concentration of product for each reading point was calculated using the 
equation  CA  where A corresponds to the absorbance represented in 
absorbance units (AU), C to the concentration of reaction product in molarity (M), ε 
to the extinction coefficient of the reaction product (=10.4 l mmol-1 cm-1) and   
(=0.2598 cm) to the path length of the sample. A linear regression analysis was 
performed on the linear region of each hydrolysis curve (where the concentration 
of product was the dependent variable and the time of reaction the independent 
variable) and only the curves with R square above 0.97 were considered for the 
determination of Vmax and Km. The reaction rate for each substrate concentration 
was given by the slope of the respective equation bmXY   (where Y 
corresponds to the concentration of reaction product represented in molarity, m to 
the slope of the straight line defined by the equation, X to the time in minutes, and 
b to the product concentration in molarity at time 0) obtained by linear regression 
analysis (Figure 25). 
In order to obtain Vmax and Km a non-linear regression analysis using the 
Michaelis-Menten equation  
 
 
 
 
(v0 corresponds to initial reaction rate, Vmax to the maximum reaction rate, Km to 
the Michaelis-Menten constant and [S] to the substrate concentration) was 
performed using  reaction rate values (dependent variable) and substrate 
concentration (independent variable). The Vmax and Km values obtained were of 
10.62 µM/min and 367.7 μM, respectively (see details on Figure 26).   
 
 
 
 
 
 
 
 SK
SV
v
m
max
0


Characterization of trypsin inhibition by boophilin 
 
 
89 
 
 
Figure 25 – Kinetic reaction of trypsin in presence of different substrate concentrations. A – Linear 
region of the hydrolysis curves obtained by incubating trypsin with different substrate 
concentrations. B – Linear regression analysis performed on the data present in A. The reaction 
rate of each reaction was given by the slope of the equation obtained by linear regression analysis 
(bold). 
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Figure 26 – Determination of maximum reaction rate and Michaelis-Menten constant of trypsin 
against Bz-Phe-Val-Arg-pNA. A – Graphic representation showing the reaction rate of trypsin in 
presence of different substrate concentrations. B – Statistical data obtained by non-linear analysis 
using the Michaelis-Menten equation. 
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3.11. Determination of the inhibition constant of D1D2 and D1 towards 
bovine trypsin 
 
The inhibition constant (Ki) is a measure of the affinity between an inhibitor 
and an enzyme. This parameter is a dissociation constant that gives the inhibitor 
concentration required to produce half of the maximal inhibition. As a dissociation 
constant, a lower Ki indicates that the inhibitor does not dissociate easily from an 
enzyme, which is translated by a more effective inhibition.  
One way of understanding the inhibition mechanism of a specific inhibitor is 
to measure the enzyme velocity at a variety of inhibitor concentrations. Thus, 
trypsin was incubated with different concentrations of D1D2 or D1, and after 
adding the substrate the kinetic reaction was monitored by measuring the 
absorbance at 405 nm for 1 hour (measurements every 15 seconds) at 37 ºC.  
The concentration product at each reading point was calculated using the 
equation  CA  where A corresponds to the absorbance represented in AU, C to 
the concentration of reaction product in molarity, ε to the extinction coefficient of 
the reaction product (=10.4 l mmol-1 cm-1) and   (=0.5196 cm) to the path length of 
the sample. A linear regression analysis was performed on the linear region of 
each hydrolysis curve (where the concentration of reaction product and the 
reaction time were the dependent and the independent variables, respectively) and 
only the curves with R square above 0.97 were considered for the determination of 
the reaction rate. The reaction rate was given by the slope of the equation 
bmXY   (Y corresponds to the concentration of reaction product represented in 
molarity, m to the slope of the straight line defined by the equation, X to the time in 
seconds, and b to the concentration of reaction product in molarity at time 0) 
obtained by linear regression analysis (Figures 27 and 28).  
The inhibition constants were obtained by non-linear regression analysis 
using the Morrison equation  
 
 
 
 
    
        
  

















 



0
0
2
appI0
appI00
E2
IE4KIE
KIE1vv
Characterization of trypsin inhibition by boophilin 
 
 
92 
 
(v is the measured reaction rate, v0 is the reaction rate in the absence of inhibitor, 
[E]0 is the total enzyme concentration, [I] is the added inhibitor concentration and 
KI-app is the apparent equilibrium inhibitor constant) on the reaction rate values 
(dependent variable) and inhibitor concentrations (independent variable) (Figures 
29 and 30). The inhibition constant determined for D1D2 was 2.366x10-2 ± 
2.976x10-2 nM and for D1 was 0.9438x10-2 ± 2.873x10-2 nM.  The inhibition 
constant determined for D1D2 was approximately two times higher than the value 
obtained for D1. This can be explained by the flexibility of the D1D2-trypsin 
complex. Assuming that the inhibition of trypsin by D1D2 is achieved by the Lys31 
of the first Kunitz domain, the second domain would remain free and the D1D2 
would be very flexible. This flexibility could lead to an increase of the dissociation 
of D1D2-trypsin complex. On the other hand, the interval in which the Ki values of 
D1 and D1D2 diverge were overlapped and thus the differences observed were not 
significant. The results obtained support the hypothesis that the second domain of 
boophilin is not involved in trypsin inhibition. However, the elucidation of the 
inhibition mechanism requires additional data from other techniques such as X-ray 
crystallography. 
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Figure 27 – Determination of trypsin reaction rate in presence of different D1D2 concentrations. A – 
Linear region of the hydrolysis curves obtained by incubating trypsin with different D1D2 
concentration. B – Linear regression analysis performed on the data present in A. The reaction rate of 
trypsin for each inhibitor concentration was given by the slope of the equation obtained by linear 
regression analysis (bold). 
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Figure 28 – Determination of trypsin reaction rate in presence of different concentrations of D1. A – 
Linear region of the hydrolysis curves obtained by incubating trypsin with different concentrations of 
D1. B – Linear regression analysis performed on the data present in A. The reaction rate of trypsin 
for each D1 concentration was given by the slope of the respective equation obtained by linear 
regression analysis (bold). 
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Figure 29 – Determination of the inhibition constant of D1D2 towards trypsin. A – Graphic obtained 
after non-linear regression analysis using the Morrison equation showing the decrease of the 
reaction rate of trypsin with the increase of D1D2 concentration. B – Statistic data obtained by non-
linear analysis using the Morrison equation, where Vo is the enzyme velocity in the absence of 
inhibitor, [T] is the trypsin concentration used, Ki is the inhibition constant obtained, [S] is the 
substrate concentration used, and Km is the Michaelis-Menten constant of trypsin against the 
substrate used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Best-fit values   
Vo 63.54 nM/sec 
[T]  3000 nM 
Ki 2.386x10
-2
 nM 
[S] 200000 nM 
Km 367400 nM 
Standard Error   
Vo 2.226 nM/sec 
Ki 2.976x10
-2
 nM 
95% Confidence Intervals   
Vo 58.27 to 68.80 nM/sec 
Ki -0.04653 to 0.09425 nM 
Goodness of Fit   
Degrees of Freedom 7 
R square 0.9810  
Absolute Sum of Squares 117.7 nM
2
 
Sy.x 4.101 nM 
Number of points   
Analyzed 9 
 
0 10 20 30
0
20
40
60
80
[D1D2] nM
V
 (
n
M
/s
e
c
)
A 
B 
Characterization of trypsin inhibition by boophilin 
 
 
96 
 
 
Figure 30 – Determination of the inhibition constant of D1 towards trypsin. A – Graphic obtained 
after non-linear regression analysis with the Morrison equation showing the decrease of the 
reaction rate of trypsin with the increase of D1 concentration. B – Statistic data obtained by non-
linear regression analysis using the Morrison equation, where Vo is the enzyme velocity in the 
absence of inhibitor, [T] is the trypsin concentration used, Ki is the inhibition constant obtained, [S] 
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is the substrate concentration used, and Km is the Michaelis-Menten constant of trypsin against the 
substrate used. 
 
 
3.12. D1 crystallization 
 
X-ray crystallography has been used to study the interaction between 
proteins. As the name suggests, for application of X-ray diffraction to a 
macromolecule it must be first crystallized. The crystallization step has emerged as 
a primary obstacle in macromolecular crystallography since the highly dynamic 
structure of proteins interferes with the crystallization process. Because there is 
strong data supporting the hypothesis that the second domain of boophilin is not 
necessary for the inhibition of trypsin, the crystallization of the D1D2 in complex 
with trypsin could be very difficult. Once the second domain of boophilin does not 
interact with trypsin, it would remain free and boophilin would be very flexible. This 
flexibility produces a very heterogeneous sample, which frequently affects 
crystallization. Because D1 seems to be the only domain of boophilin that interacts 
with trypsin, the problem of the complex flexibility could be solved by using the 
trypsin-D1 complex instead of trypsin-D1D2 complex to study the inhibition 
mechanism of boophilin against trypsin. However, it is first necessary to confirm 
that the isolated first domain of boophilin exhibits a conformation similar to the first 
domain of D1D2. In order to determine the crystallographic structure of D1, this 
protein was first crystallized. 
Crystallization assays were setup with purified recombinant D1 using the 
sitting drop method. In sitting drop vapour diffusion the drop containing the protein 
solution combined with precipitant solution is dispensed onto a small platform, 
which is contiguous through the vapour phase with a reservoir of much larger 
volume. A group of very small needle crystals was observed 13 days after the 
incubation of D1 solution with the precipitant (Figure 31, A). Cuboidal crystals 
started to grow from this group being observed for the first time on the 34th day 
(Figure 31, B). Their growth was followed for 4 months (Figure 31) after which the 
size of the crystals did not seem to increase. Afterward some crystals were cryo-
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cooled in liquid nitrogen. One of these cryo-cooled crystals was subjected to X-ray 
diffraction (section 3.13) and the collected data was used to determine the 
crystallographic structure of D1 (section 3.14). 
 
 
 
Figure 31 – Appearance and growth of D1 crystals. The drop contained equal volumes of D1 
solution and precipitant. Growth was followed for 4 months. The needle crystals group (large arrow) 
and cuboidal crystals (thin arrows) were first observed on the 13
rd
 day (A) and 34
th
 day (B), 
respectively. The crystal growth was followed (C – 57
th
 day; D – 85
th
 day) until the day of their 
collection (E – 102
th 
day) (Scale bars, 0.2 mm). 
A B 
D C 
E 
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3.13. Data collection, processing and refinement 
 
Diffraction data to 1.80 Å was collected from a single cryo-cooled (100 K) 
D1 crystal. The crystal measured belonged to the orthorhombic space group 
P212121, with unit cell constant of a = 24.81 Ǻ, b = 30.74 Ǻ, c = 54.97 Ǻ, and had 
an unusual low solvent content of about 23%. The molecular coordinates of the 
first domain of boophilin (residues Gln16 to Ala58) in complex with thrombin from 
PDB entry 2ODY (Macedo-Ribeiro et al., 2008) were used as a search model to 
solve the structure of D1. The model was subjected to alternating cycles of manual 
building with Coot (Emsley et al., 2010) and refinement with PHENIX (Adams et 
al., 2010). The data-collection, processing and refinement statistics are 
summarized in Table 4. 
 
 
Table 4 – Statistics of data collection and refinement. 
Crystallographic analysis 
Resolution range (Ǻ) 14.74 – 1.80 
Space group P212121 
Unit cell dimensions (Ǻ) 
a = 24.8 
b = 30.7 
c = 55.0 
Multiplicity (overall/outer shell) 5.1/2.5 
Rmerge
a
 (overall) 0.058 
Completeness (%) (overall/outer shell) 97.19/87.6 
I/σ (I) (overal/outer shell) 7.1/5.1 
Mathews coefficient (Ǻ
3
 Da
-1
) 1.60 
Solvent content (%) 23.3 
Structure Refinement 
Rfactor
b
/Free Rfactor
c
 (%) 0.1400/0.1689 
Nº of unique reflections (working/test set)  3894/182 
Water molecules 68 
Total number of non-hydrogen atoms 511 
Number of protein non-hydrogen atoms 443 
Average overall B-factor (Ǻ
2
) 9.79 
Average protein B-factor (Ǻ
2
) 8.17 
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Average water B-factor (Ǻ
2
) 20.31 
r.m.s.d. bond lengths (Ǻ) 0.014 
r.m.s.d. bond angles (º) 1.423 
Ramachandran plot statistics 
Residues in allowed regions 55 (98.21%) 
Residues in disallowed regions 0 (0%) 
Estimated coordinate error 
E.s.d. from Luzzati plot (Ǻ) 0.2574 
DPI
d 
(Ǻ) 0.1067 
 
 
 
3.14. D1 structure 
 
 The crystallographic structure of D1 presents a canonical Kunitz fold domain 
composed by two anti-parallel β-sheets followed by an α-helix. The structure is 
maintained by the presence of three disulfide bridges established between Cys21-
Cys71, Cys30-Cys54 and Cys46-Cys67 (Figure 32). 
The structure of D1 by itself reveals a conformation that is similar to the 
conformation of the first domain (residues Gln16 to Ala58) in the context of the 
D1D2 in complex with thrombin (PDB entry 2ODY) (Macedo-Ribeiro et al., 2008) 
(see superposition of the two structures in Figure 33). The reactive site loop of the 
first domain of D1D2 presumably involved in trypsin inhibition is preserved in D1. 
The mutation found in D1 (Glu27Gln27) by DNA sequencing did not introduce 
any significant structure modifications (Figure 33). Since D1 protein by itself seems 
a
Rmerge = hi|Ihi–<Ih>|/hi<Ih>, where Ihi is the observed intensity of the i-th measurement of 
reflection (h), including symmetry-related ones, and <Ih> is the mean intensity of the i 
observations of reflection h over all measurements of Ihi. 
b
Rfactor  = ||Fo|–|Fc||/|Fo|, where |Fo| and |Fc| are observed and calculated structure factor 
amplitudes, respectively. 
c
Free Rfactor is the cross-validation R-factor computed for a randomly chosen subset of 5% of 
the total number of reflections, which were not used during refinement. 
d
Diffraction-data precision indicator 
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to fold correctly, we hypothesize that this might be a suitable protein to study the 
interaction between trypsin and boophilin. Besides the disulfide bonds, no 
additional post-translational modifications were observed. This fact validates the 
use of Pichia pastoris as an expression system for the production of D1. Additional 
post-translational modifications, such as glycosylation, could affect not only the 
activity/affinity of D1, but also its crystallization. 
 
 
 
Figure 32 – Crystallographic structure of D1. The structure of D1 shows two anti-parallel β-sheets 
followed by an α-helix. The structure is maintained by the presence of three disulfide bridges 
(orange). 
 
 
 
 
 
 
 
 
 
 
 
N 
C 
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Figure 33 – Crystallographic structure of D1 (blue) aligned with the first domain of D1D2 (orange). 
The structure of D1 reveals a conformation similar to the structure of the first domain of full-length 
boophilin. The mutation found (residue position 27) by DNA sequencing does not affect the 
structure of the D1. It is also possible to observe that the reactive-loop (containing K31) is 
preserved. 
 
 
3.15. Trypsin-D1 complex purification 
 
With the aim of crystallizing D1 in complex with trypsin for better 
understanding the mechanism of inhibition of trypsin by boophilin, thrombin-D1 
complexes were prepared.  The trypsin-D1 complex was formed by incubating 
trypsin with a molar excess of D1 (mixture). This excess of D1 was used to ensure 
that all trypsin molecules were in complex with a D1 molecule. After incubation, 
excess D1 was removed by a size-exclusion chromatography (Figure 34, A), which 
promotes the separation of the complex from free D1 according to their size 
differences. The chromatogram of the mixture shows a higher peak followed by 
two smaller peaks. In comparison with the chromatogram obtained after performing 
K31 
Q27 
E27 
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a size exclusion chromatography under the same conditions of trypsin (23.8 kDa) 
alone, the higher peak produced by the mixture was eluted before trypsin. This 
result indicates that the peak corresponds to the higher molecular weight trypsin-
D1 complex (30.2 kDa). The two smaller peaks, eluted after trypsin, correspond to 
the free D1 and degradation products.  
The fractions containing the peaks of elution were analysed by SDS-PAGE. 
It is not possible to confirm the presence of a complex by this technique; however, 
it is able to show the presence or absence of trypsin and boophilin in the same 
fraction and also the degradation degree or contamination. On SDS 
polyacrylamide gel the fractions corresponding to the higher peak showed the 
presence of trypsin, D1 and degradation products of trypsin (Figure 34, B, lanes 
25-27), while the smaller peaks showed a light band of trypsin and two close small 
molecular weight bands. From these two bands, the one with higher molecular 
weight corresponds to D1 and the other to degradation products. A closer 
observation of the most concentrated fractions of the higher peak reveals also the 
presence of this small molecular weight band. It is possible that this small 
molecular weight band corresponds to cleaved D1. During trypsin-D1 interaction 
trypsin probably cleaves the reactive-loop of the D1 without releasing the reaction 
product and thus becoming inhibited. After treating the complex with β-
mercaptoethanol and incubating at 95 ºC for 10 minutes the complex dissociates 
and the disulfide bonds (between Cys21-Cys71 and Cys30-Cys54) that connect 
the two segments of cleaved D1 are broken. The two fragments produced should 
be Gln16-Lys31 (1806.0 Da) and Ala32-Ala58 (4589.0 Da). The first fragment is 
too small and should be undetectable in a SDS polyacrylamide gel.  The second 
fragment has almost the molecular weight of D1 (6377.1 Da) and could correspond 
to the smaller molecular weight band observed. 
Only fractions 25-27 were pooled together in order to prevent the 
contamination with non-complexed proteins. The pool of these fractions was 
concentrated and used in crystallization assays (see section below). 
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Figure 34 – Purification of 1:1 trypsin-D1 complex by size exclusion chromatography. A – 
Chromatogram obtained during the purification of the complex from the mixture (Light blue curve). 
The complex is eluted first (*) compared to trypsin (arrow) followed by the excess of inhibitor (**). 
The pooled fractions are represented by orange arrows and the other analyzed fractions by yellow 
arrows. B – Ten microlitres of D1 (D1), 1μl of trypsin (T1), 1μl of trypsin incubated on ice during 12 
hours (T2) , 10 µl of the mixture (M), 1 µl of concentrated mixture injected into the column (I), 5 µl of 
fractions 20-28, 10 µl of fractions 29-38, 3 µl of the pool of fractions 25-27 (P) and 1 µl of 
concentrated pool (C) were separated in a 17% SDS polyacrylamide gel. Fractions 25-27 show the 
bands correspondent to trypsin (T), D1 (D1) and products of trypsin degradation (DT). Fractions 34-
36 shows two bands, in which one (*) of them has a smaller apparent molecular weight than D1.  
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3.16. Trypsin-D1 complex crystallization 
 
Crystallization assays were setup with an in vitro complex composed by 
commercial bovine trypsin and purified recombinant D1. Fragile crystal plates were 
obtained by incubating the complex solution with an equal volume of precipitant. 
These crystals were observed for the first time 7 days after the incubation with the 
precipitant solution (Figure 32, A) and their growth was more significant until the 
12nd day. Crystals were cryo-cooled in liquid nitrogen at the 80th day (Figure 32, E). 
These crystals were measured at the European Synchrotron Radiation Facility 
(ESRF, Grenoble, France). However, they were too fragile, being destroyed by X-
ray radiation before a complete data set was obtained.   
In order to find a condition in which better crystals could grow new 
precipitant solutions were prepared by varying the pH and the concentration of 
precipitant. However, no crystals were obtained in these new precipitant solutions. 
It was possible to reproduce the crystals by incubating the trypsin-D1 complex 
solution with the precipitant solution of the commercial kit. However, no crystals 
were obtained in a solution with a similar composition prepared in our laboratory, 
even using the same batch of complex solution. The water used to prepare the 
precipitant solution could be the reason why we are not able to obtain crystals with 
our precipitant solution. In order to confirm this possibility, new solutions should be 
prepared using the same water used in the commercial precipitant.  
Besides the optimization of the condition where the crystals were found, 
new conditions should be tested in order to find other that also promote 
crystallization of the complex. These new conditions involve not only new 
precipitant solutions (new crystallization screens and additive screens), but also 
different crystallization methods (e.g. hanging drop) and even different 
temperatures (e. g. 4 ºC and room temperature).  
Moreover, the complex solution used in the crystallization assays had 
contaminants (see Figure 34, B) that could interfere with the crystallization of the 
complex. Thus, an additional purification step could be required. 
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Figure 35 – Crystals obtained by incubating complex solution with the precipitant. Crystal plates 
(arrows) were first observed on the 7
th
 day (A). The crystals growth was followed (B – 12
nd 
day; C – 
30
th
 day; D – 60
th
 day) until the day of their collection (80
th
 day). The crystals were fragile and crush 
very easily (E - 80
th
 day after collecting some crystals fragments) (Scale bars, 0.2 mm). 
 
 
 
 
 
 
 
E 
C D 
A B 
Characterization of trypsin inhibition by boophilin 
 
 
107 
 
Characterization of trypsin inhibition by boophilin 
 
 
108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Conclusion 
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Pichia pastoris has many of the advantages of higher eukaryotic expression 
systems such as protein processing, folding, and posttranslational modification. 
Cell manipulation is almost as easy as in E. coli and generally gives higher 
expression levels.  However, the growth and expression times are much longer 
(Cereghino and Cregg, 2000). 
The Pichia pastoris expression system proved to be an adequate system for 
expression of D1D2 and D1. Both recombinant proteins were expressed at high 
levels and correctly folded, as confirmed by the ability to inhibit trypsin and/or 
thrombin.  
This expression system has also an additional advantage. Pichia pastoris 
secrets only low levels of its own proteins (Cereghino and Cregg, 2000). This 
feature associated to the secretion of recombinant proteins, as a consequence of 
their fusion with the α-factor secretion signal from S. cerevisiae, is a great first step 
of purification. The secretion of the recombinant proteins not only avoids all the 
work associated to cell lysis but also promotes the easy separation of the 
recombinant proteins from all cellular components. The advantage of this feature 
was confirmed specially in D1 purification, in which a single affinity 
chromatography in an immobilized-trypsin column produced highly pure protein. In 
the case of D1D2, an additional chromatography was required. The D1D2 seems 
to be unstable and the degradation occurred during protein expression produced a 
band on a SDS polyacrylamide gel with an apparent molecular weight similar to D1 
(approximately 10 kDa). This result suggests that the degradation occurred in the 
inter-domain linker, producing probably D1 and D2. The presence of D2 was not 
confirmed but since it has low affinity for trypsin it is probably eliminated during the 
affinity chromatography step. On the other hand, D1 shows a high affinity for 
trypsin, being eluted with D1D2 during the affinity chromatography. In order to 
separate D1D2 from D1 an additional chromatography was performed based on 
their charge difference. At pH 8.0, D1 and D1D2 showed a significant charge 
difference that allowed their separation by ion-exchange chromatography using an 
anion exchanger. At the end of this additional purification step D1D2 was highly 
pure.  
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The high purity of D1 and D1D2 was required for the determination of their 
inhibition constants and crystallization. Despite the inhibition constant determined 
for D1D2 being two times higher than the inhibition constant determined for D1, the 
intervals in which they diverge were overlapped. Thus, no significant differences 
were observed between the inhibitory activity of D1 and D1D2 against trypsin. This 
finding supports the hypothesis that the second domain of boophilin is not required 
for trypsin inhibition. However, additional data are required clarify the inhibition 
mechanism used by boophilin against trypsin, such as X-ray crystallography study 
of boophilin in complex with trypsin.  
The only technique that allows direct visualization of protein structure at the 
atomic or near atomic level is X-ray crystallography. As the name suggests, for the 
application of X-ray diffraction, the macromolecule must be first crystallized. 
However, not only must crystals be grown, but they must be reasonably large, 
high-quality crystals that are suitable for a high-resolution X-ray diffraction analysis. 
The crystallization step has emerged as the primary obstacle in X-ray 
crystallography. There is no comprehensive theory that could guide our efforts to 
crystallize a particular protein and thus the approaches to protein crystallization 
remain largely empirical and demand patience and perseverance (McPherson, 
2004). It is a matter of searching, as systematically as possible, and wait for 
success to smile. There are many factors that affect the crystallization of proteins 
and some of them are summarized in Table 5.  
 
 
Table 5 – Factors affecting crystallization (McPherson, 2004). 
Physical Chemical Biochemical 
Temperature pH Purity 
Surface Precipitant type 
Aggregation state of 
macromolecules 
Methodology Precipitant concentration 
Post-translational 
modifications 
Gravity Ionic strength Source of macromolecules 
Pressure Supersaturation degree Proteolysis/hydrolysis 
Vibrations 
Reductive/oxidative 
environment 
Chemical modifications 
Characterization of trypsin inhibition by boophilin 
 
 
112 
 
Electrostatic/magnetic fields Macromolecules concentration 
Inherent symmetry of the 
macromolecule 
Dielectric properties Metal ions Macromolecule stability 
Viscosity Crosslinkers/polyions Isoelectric point 
Equilibration rate 
Detergents, surfactants, 
amphophiles 
History of the sample 
Homogeneous/heterogeneous 
macromolecules 
Non-macromolecular 
impurities 
Ligands/inhibitors/effectors 
   
 
 
One of the factors that affect the crystallization is the heterogeneity of the 
sample. This heterogeneity can be produced not only by different molecular 
species but also by different conformations of the same molecule. This means that 
a flexible molecule is less likely to crystallize than a static one. The trypsin-D1D2 
complex would certainly have this problem. During inhibition of trypsin, the second 
domain of boophilin would be able to move freely, producing complex molecules 
with different symmetries. Because the first domain seems to be the only domain 
of boophilin to interact with trypsin, the flexibility issue could be avoided by using 
the trypsin-D1 instead of the trypsin-D1D2 complex to study the inhibition of trypsin 
by boophilin. However, for this to be possible D1 must have a conformation similar 
to the first domain of D1D2. The crystallographic structure obtained for D1 shows 
no significant differences compared to the first domain of D1D2, and thus, the use 
of trypsin-D1 complex to study the inhibition of trypsin by boophilin is validated. 
The trypsin-D1 complex was incubated with about 720 precipitant solutions, 
including commercial crystallizations screens and optimization solutions. Some 
crystals were obtained but most of them were of very bad quality, totally unsuitable 
for X-ray analysis. The best crystals obtained were those presented on this thesis, 
but even those were too sensitive to the X-ray radiation.  
As showed above, the number of factors that affect crystallization is 
extremely high and a very small variation in a parameter (e.g. temperature, protein 
concentration, precipitant pH) could be the difference between have or does not 
have crystals. Therefore, the number of conditions that can be used in order to find 
one able to produce high-quality crystals is huge.  
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In the case of trypsin-D1 complex, beside the use of new precipitant 
solutions that combine different salts, crystallizing agents and pH (and also 
different concentrations of each), other conditions such as temperature (4ºC) and 
crystallization method (hanging drop) could also be used. However, because so 
many precipitant solutions were used with no success, the main problem could be 
the protein complex itself. The trypsin-D1 complex could also be flexible or have 
symmetry that disfavour the perfect fit between the molecules, giving rise to the 
fragile crystals obtained. This problem could force the use of a different approach 
to study the inhibition mechanism of trypsin and boophilin. A ternary complex 
composed by trypsin-boophilin-thrombin could be more stable compared to trypsin-
D1 complex and may be easier to crystallize. Another problem that could be 
affecting the crystallization of trypsin-D1 complex is the presence of contaminants 
in the complex solution. As confirmed by SDS-PAGE, the complex purified by size-
exclusion chromatography showed bands of trypsin degradation. In spite of some 
proteins being able to crystallize from very heterogeneous mixtures, in general, 
however, the likelihood of success in crystal growth is greatly advanced by 
increased homogeneity. Therefore, another approach to produce better crystals is 
to use a more homogeneous complex solution that could be obtained by an 
additional purification step. 
 
 
.  
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I. Bacterial culture media and solutions 
 
a. Bacterial culture media 
 
i. Luria-Bertani (LB) medium  
 
1% tryptone 
1% NaCl 
0.5% yeast extract 
 
Dissolve tryptone, NaCl and yeast extract in deionised 
water. For LB agar plates, add 15 g of agar per litre of 
medium. Sterilize by autoclaving. 
 
 
ii. Super optimal broth medium (SOC medium) 
 
0.5% yeast extract 
2% tryptone 
10 mM NaCl 
2,5 mM KCl 
10 mM MgCl2 
10 mM MgSO4 
20 mM glucose 
 
Dissolve yeast extract, tryptone, NaCl, KCl, MgCl2 and 
MgSO4 in deionised water and sterilize by autoclaving. Let the 
solution cool down and add glucose. Sterilize the final solution 
by passing it through a 0.2 μm filter. 
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iii. Low Salt Luria-Bertani (Low Salt LB) medium  
 
1% tryptone 
0.5% NaCl 
0.5% yeast extract 
  
Dissolve tryptone, yeast extract and NaCl in deionised 
water. Adjust pH to 7.5 with 1 M NaOH. For Low Salt LB agar 
plates, add 15 g of agar per litre of medium. Sterilize by 
autoclaving.  
 
 
b. Competent cell solutions 
 
i. TFB I 
  
For a final volume of 200 ml, dissolve in sterile water 0.6 
g of potassium acetate, 2.4 g of rubidium chloride, 0.294 g of 
calcium chloride and 2.0 g of manganese (II) chloride and add 
30.8 ml of glycerol. Adjust the pH to 5.8 with 0.2 M acetic acid. 
Sterilize by filtering the solution through a 0.2 μm pore filter. 
Store the solution at -20ºC.  
 
 
ii. TFB II 
 
For a final volume of 100 ml, dissolve 0.24 g of MOPS 
sodium salt, 1.1 g of calcium chloride, 0.12 g rubidium chloride 
and add 15.4 ml of glycerol. Adjust the pH to 6.5 with 0.5 M 
sodium hydroxide. Sterilize by filtering the solution through a 
0.2 μm pore filter. Store the solution at -20ºC. 
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II. Yeast culture media and solutions 
 
a. Yeast culture media 
 
i. Yeast extract peptone dextrose medium (YPD) 
 
1% yeast extract 
2% BactoTM peptone 
2% dextrose (glucose) 
 
  
For a final volume of 1000 ml, dissolve 10 g of yeast 
extract and 20 g of BactoTM peptone in 900 ml of deionised 
water. For YPD agar plates add 20 g of agar. Autoclave for 20 
minutes on liquid cycle. Add 100 ml of 10x dextrose (Appendix 
II, b, v). 
 
 
ii. Buffered glycerol-complex medium (BMGY) 
 
1% yeast extract 
2% BactoTM peptone 
100 mM potassium phosphate pH 6.0 
1.34% yeast nitrogen base without amino acids (YNB) 
4x10-5% biotin 
1% glycerol 
 
For a final medium volume of 1000 ml, dissolve 10 g of 
yeast extract and 20 g of BactoTM peptone in 700 ml of 
deionised water.  After autoclaving during 20 minutes on liquid 
cycle, allow it to cool down to room temperature, and then add 
100 ml of 1 M potassium phosphate buffer pH 6.0 (Appendix II, 
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b, ii), 100 ml of 10x YNB (Appendix II, b, iii), 2 ml of 500x biotin 
(Appendix II, b, iv) and 100 ml of 10x glycerol (Appendix II, b, 
vi). 
   
 
 
iii. Buffered methanol-complex medium (BMMY) 
 
1% yeast extract 
2% BactoTM peptone 
100 mM potassium phosphate pH 6.0 
1.34% yeast nitrogen base without amino acids (YNB) 
4x10-5% biotin 
0.5% methanol 
 
For a final medium volume of 1000 ml, dissolve 10 g of 
yeast extract and 20 g of BactoTM peptone in 700 ml of 
deionised water.  After autoclaving during 20 minutes on liquid 
cycle, allow it to cool down to room temperature, and then add 
100 ml of 1 M potassium phosphate pH 6.0 (Appendix II, b, ii), 
100 ml of 10x YNB (Appendix II, b, iii), 2 ml of 500x biotin 
(Appendix II, b, iv) and 100 ml 10x methanol (Appendix II, b, 
vii). 
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b. Solutions 
 
i. Lysis buffer 
 
10 mM Tris-HCl pH 8.0 
100 mM NaCl 
1 mM EDTA 
2% Triton X-100 
1% SDS 
 
ii. 1 M Potassium phosphate pH 6.0 
 
For a final volume of 1000 ml, combine 132 ml of 1 M of 
potassium phosphate dibasic with 868 ml of 1 M of potassium 
phosphate monobasic and confirm that the pH = 6.0 ± 0.1. If the 
pH needs to the adjusted, use phosphoric acid or potassium 
hydroxide. Sterilize by autoclaving. 
 
 
iii. 10x Yeast nitrogen base without amino acids (YNB) 
 
2% potassium phosphate monobasic 
10% ammonium sulphate 
1% magnesium sulphate 
0.2% sodium chloride 
0.2% calcium chloride 
4x10-3% myo-inositol  
 
 For a final volume of 1000 ml, add 20 g of potassium 
phosphate monobasic, 100 g of ammonium sulfate, 10 g of 
magnesium sulfate, 2 g of sodium chloride, 2 g of calcium 
chloride and 40 mg of myo-inositol to deionised water. Heat 
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the solution in order to dissolve. Sterilize by filtering the 
solution through a 0.2 μm pore filter. 
 
 
iv. 500x Biotin (0.02% Biotin) 
 
Dissolve 10 mg of biotin in 50 ml of deionised water and 
sterilize by filtering through a 0.2 μm pore filter. 
 
 
v. 10x Dextrose (20% dextrose) 
Dissolve 200 g of dextrose (D-glucose) in 1000 ml of 
sterile water and sterilize by autoclaving. 
 
 
vi. 10x Glycerol (10% Glycerol) 
 
Mix 100 ml of glycerol with 900 ml of deionised water 
and sterilize by autoclaving. 
 
 
vii. 10x Methanol (5% methanol) 
  
 Mix 5 ml of methanol with 95 ml of deionised water and 
sterilize by filtering through a 0.2 μm pore filter.  
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III. Plasmid 
 
 
 
 
Figure 36 – Map of pPICZαB vector. This vector has the 5’ AOX1 promoter, that allows the 
methanol-inducible, high-level expression of the gene of interest in P. pastoris; the α-factor 
secretion signal (from S. cerevisiae), which allows the efficient secretion of most proteins from P. 
pastoris cells; a multiple cloning site with two Xho I sites (†), which allow the cloning of the interest 
gene in frame with Kex2 cleavage site, resulting in expression of the gene without additional amino 
acids in the N-terminus; the c-myc epitope for the detection of recombinant fusion protein with an 
anti-myc antibody; an C-terminal polyhistidine tag, that allows the purification of the recombinant 
fusion protein on a metal-chelating resin and also the detection of the recombinant fusion protein 
with a anti-his antibody; the AOX1 transcription terminator (TT) region that permits efficient 3’ 
mRNA processing for increased mRNA stability; The TEF1 promoter (from S. cerevisiae) which 
drives the expression of the Zeocin
TM
 resistance gene in P. pastoris; the EM7 promoter (synthetic 
prokaryotic promoter), that drives constitutive expression of the Zeocin
TM
 resistance gene in E. coli; 
the Zeocin
TM
 resistance gene (Sh ble) for the selection of transformants in E.coli and P. pastoris; 
the CYC1 transcription termination region (3’ end of S. cerevisiae CYC1 gene), that allows efficient 
3’ mRNA processing of the Zeocin
TM
 resistance gene for increased stability; and the pUC origin, 
which allows the replication and maintenance of the plasmid in E.coli. 
